Bausch Health Companies (BHC) 10-Q 30 Apr 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 27, 2015
Document and Entity Information
Entity Registrant Name	Valeant Pharmaceuticals International, Inc.
Entity Central Index Key	885590
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding		342,479,119

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Current assets:
Cash and cash equivalents	$1,864.40	$322.60
Trade receivables, net	2,108.80	2,075.80
Inventories, net	998.9	950.6
Restricted cash and cash equivalents (Note 8)	10,354.90	9.1
Prepaid expenses and other current assets	660.9	632.8
Assets held for sale	7.8	8.9
Deferred tax assets, net	196.5	193.3
Total current assets	16,192.20	4,193.10
Property, plant and equipment, net	1,334.80	1,310.50
Intangible assets, net	11,554.60	11,255.90
Goodwill	9,161.40	9,346.40
Deferred tax assets, net	151.7	54
Other long-term assets, net	171.2	193.1
Total assets	38,565.90	26,353
Current liabilities:
Accounts payable	352.5	398
Accrued and other current liabilities	2,424.40	2,179.40
Acquisition-related contingent consideration	186.3	141.8
Current portion of long-term debt	122.8	0.9
Deferred tax liabilities, net	11.1	10.7
Total current liabilities	3,097.10	2,730.80
Acquisition-related contingent consideration	198.9	167
Long-term debt	25,897.90	15,253.70
Pension and other benefit liabilities	227.7	239.8
Liabilities for uncertain tax positions	98.7	102.6
Deferred tax liabilities, net	2,261.50	2,227.50
Other long-term liabilities	208.9	197.1
Total liabilities	31,990.70	20,918.50
Commitments and contingencies (Note 15)
Equity
Common shares, no par value, unlimited shares authorized, 342,266,409 and 334,402,964 issued and outstanding at March 31, 2015 and December 31, 2014, respectively	9,810.30	8,349.20
Additional paid-in capital	260.9	243.9
Accumulated deficit	-2,291.30	-2,365
Accumulated other comprehensive loss	-1,327.60	-915.9
Total Valeant Pharmaceuticals International, Inc. shareholders’ equity	6,452.30	5,312.20
Noncontrolling interest	122.9	122.3
Total equity	6,575.20	5,434.50
Total liabilities and equity	$38,565.90	$26,353

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common stock, no par value (in usd per share)	$0	$0
Common stock, shares issued	342,266,409	334,402,964
Common stock, shares outstanding	342,266,409	334,402,964

CONSOLIDATED_STATEMENTS_OF_INC

CONSOLIDATED STATEMENTS OF INCOME (LOSS) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenues
Product sales	$2,146.90	$1,851.10
Other revenues	44	35.1
Total revenues	2,190.90	1,886.20
Expenses
Cost of goods sold (exclusive of amortization and impairments of finite-lived intangible assets shown separately below)	560.4	504.1
Cost of other revenues	14.3	14.3
Selling, general and administrative	573.8	482
Research and development	55.8	61.3
Amortization and impairments of finite-lived intangible assets	365.2	355.2
Restructuring, integration and other costs	55	133.6
In-process research and development impairments and other charges	0	12
Acquisition-related costs	9.8	1.5
Acquisition-related contingent consideration	7.1	8.9
Other expense (income)	6.1	-43.3
Total expenses	1,647.50	1,529.60
Operating income	543.4	356.6
Interest income	0.9	1.8
Interest expense	-297.8	-246.5
Loss on extinguishment of debt	-20	-93.7
Foreign exchange and other	-71.1	-13.4
Income before provision for income taxes	155.4	4.8
Provision for income taxes	80.9	25.1
Net income (loss)	74.5	-20.3
Less: Net income attributable to noncontrolling interest	0.8	2.3
Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.	$73.70	($22.60)
Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:
Basic (in usd per share)	$0.22	($0.07)
Diluted (in usd per share)	$0.21	($0.07)
Weighted-average common shares (in millions)
Basic (in shares)	336.8	334.9
Diluted (in shares)	343.4	334.9

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Statement of Comprehensive Income [Abstract]
Net income (loss)	$74.50	($20.30)
Other comprehensive loss
Foreign currency translation adjustment	-411.5	-7.4
Pension and postretirement benefit plan adjustments	-0.4	-0.6
Other comprehensive loss	-411.9	-8
Comprehensive loss	-337.4	-28.3
Less: Comprehensive income attributable to noncontrolling interest	0.6	1.5
Comprehensive loss attributable to Valeant Pharmaceuticals International, Inc.	($338)	($29.80)

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash Flows From Operating Activities
Net income (loss)	$74.50	($20.30)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization, including impairments of finite-lived intangible assets	407	401.1
Amortization and write-off of debt discounts and debt issuance costs	10.5	12.2
Acquisition accounting adjustment on inventory sold	24.5	5.2
Acquisition-related contingent consideration	7.1	8.9
Allowances for losses on accounts receivable and inventories	12.2	19.6
Deferred income taxes	62.5	10
Additions (reductions) to accrued legal settlements	1.5	-48.8
Payments of accrued legal settlements	-3	0
Share-based compensation	35	24.8
Tax benefits from stock options exercised	-17.9	-1.2
Foreign exchange loss	75.9	12.6
Loss on extinguishment of debt	20	93.7
Payment of accreted interest on contingent consideration	-2.2	-0.7
Other	-7.2	9.7
Changes in operating assets and liabilities:
Trade receivables	-67	-30.1
Inventories	-38.5	-69.2
Prepaid expenses and other current assets	-45.1	4.2
Accounts payable, accrued and other liabilities	-58.7	52.6
Net cash provided by operating activities	491.1	484.3
Cash Flows From Investing Activities
Acquisition of businesses, net of cash acquired	-795	-306.3
Acquisition of intangible assets and other assets	-48.8	-21.1
Purchases of property, plant and equipment	-65.8	-58.1
Proceeds from sales and maturities of short-term investments	17.7	0
Increase in restricted cash and cash equivalents (Note 8)	-10,349.10	0
Other	0.5	1.4
Net cash used in investing activities	-11,240.50	-384.1
Cash Flows From Financing Activities
Issuance of long-term debt, net of discount	12,004.40	360.6
Repayments of long-term debt	-1,110.30	-433.9
Issuance of common stock, net	1,433.70	0
Proceeds from exercise of stock options	14.5	3.5
Tax benefits from stock options exercised	17.9	1.2
Payment of employee withholding tax upon vesting of share-based awards	-15.9	-27.7
Payments of contingent consideration	-12.3	-9.7
Payments of financing costs	-26.6	-9.9
Other	0.9	-6.8
Net cash provided by (used in) financing activities	12,306.30	-122.7
Effect of exchange rate changes on cash and cash equivalents	-15.1	-1.5
Net increase (decrease) in cash and cash equivalents	1,541.80	-24
Cash and cash equivalents, beginning of period	322.6	600.3
Cash and cash equivalents, end of period	1,864.40	576.3
Non-Cash Investing and Financing Activities
Acquisition of businesses, contingent and deferred consideration obligations at fair value	-286.9	-21.7
Acquisition of businesses, debt assumed	$0	($4)

DESCRIPTION_OF_BUSINESS

DESCRIPTION OF BUSINESS	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	DESCRIPTION OF BUSINESS
	The Company is a multinational, specialty pharmaceutical and medical device company, continued under the laws of the Province of British Columbia, that develops, manufactures, and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.
	On April 1, 2015, the Company acquired Salix Pharmaceuticals, Ltd. ("Salix"), pursuant to an Agreement and Plan of Merger dated February 20, 2015, as amended on March 16, 2015 (the "Merger Agreement"), with Salix surviving as a wholly-owned subsidiary of Valeant Pharmaceuticals International ("Valeant"), a subsidiary of the Company (the "Salix Acquisition").
	For further information regarding the Salix Acquisition, including the related financing, see note 8 titled "LONG-TERM DEBT", note 11 titled "SHAREHOLDERS' EQUITY", and note 17 titled "SUBSEQUENT EVENTS".

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation
	The accompanying unaudited consolidated financial statements (the “unaudited consolidated financial statements”) have been prepared by the Company in United States (“U.S.”) dollars and in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting, which do not conform in all respects to the requirements of U.S. GAAP for annual financial statements. Accordingly, these condensed notes to the unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto prepared in accordance with U.S. GAAP that are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 (the “2014 Form 10-K”). The unaudited consolidated financial statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company’s audited consolidated financial statements for the year ended December 31, 2014. The unaudited consolidated financial statements reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations for the interim periods presented.
	Reclassifications
	Certain reclassifications have been made to prior year amounts to conform with the current year presentation.
	Use of Estimates
	In preparing the unaudited consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the unaudited consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the operating results for the interim periods presented are not necessarily indicative of the results expected for the full year.
	On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s results of operations and financial position could be materially impacted.
	Recently Issued Accounting Standards, Not Adopted as of March 31, 2015
	In May 2014, the Financial Accounting Standard Board ("FASB") and the International Accounting Standards Board issued converged guidance on recognizing revenue from contracts with customers. The core principle of the revenue model is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In applying the revenue model to contracts within its scope, an entity will: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. In addition to these provisions, the new standard provides implementation guidance on several other topics, including the accounting for certain revenue-related costs, as well as enhanced disclosure requirements. The new guidance requires entities to disclose both quantitative and qualitative information that enables users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The guidance is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016. Early application is not permitted. Entities have the option of using either a full retrospective or a modified approach to adopt the guidance. The Company is evaluating the impact of adoption of this guidance on its financial position and results of operations.
	In August 2014, the FASB issued guidance which requires management to assess an entity’s ability to continue as a going concern and to provide related disclosures in certain circumstances. Under the new guidance, disclosures are required when conditions give rise to substantial doubt about an entity’s ability to continue as a going concern within one year from the financial statement issuance date. The guidance is effective for annual periods ending after December 15, 2016, and all annual and interim periods thereafter. Early application is permitted. The adoption of this guidance will not have any impact on the Company’s financial position and results of operations and, at this time, the Company does not expect any impact on its disclosures.
	In February 2015, the FASB issued guidance which amends certain consolidation requirements. The new guidance has the following stipulations, among others: (i) eliminates the presumption that a general partner should consolidate a limited partnership and eliminates the consolidation model specific to limited partnerships, (ii) clarifies when fees paid to a decision maker should be a factor to include in the consolidation of variable interest entities (“VIEs”), (iii) amends the guidance for assessing how relationships of related parties affect the consolidation analysis of VIEs, and (iv) reduces the number of VIE consolidation models from two to one by eliminating the indefinite deferral for certain investment funds. The guidance is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2015. Early application is permitted. Entities have the option of using either a full retrospective or a modified retrospective approach to adopt the guidance. The Company is evaluating the impact of adoption of this guidance on its financial position and results of operations.
	In April 2015, the FASB issued guidance which requires debt issuance costs to be presented in the balance sheet as a direct deduction from the carrying value of the associated debt, consistent with the presentation of a debt discount. The guidance is effective for annual periods beginning after December 15, 2015, and all annual and interim periods thereafter. Early application is permitted. The adoption of this guidance, which will be applied retrospectively, will not have a material impact on the Company’s financial position and results of operations, as it will impact balance sheet presentation only.

BUSINESS_COMBINATIONS

BUSINESS COMBINATIONS	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
BUSINESS COMBINATIONS	BUSINESS COMBINATIONS
	The Company’s business strategy involves selective acquisitions with a focus on core geographies and therapeutic classes.
	(a) Business combinations in 2015 included the following:
	In the three-month period ended March 31, 2015, the Company completed certain business combinations, which included the February 23, 2015 acquisition of the assets of Dendreon Corporation ("Dendreon") and the February 10, 2015 acquisition of certain assets of Marathon Pharmaceuticals, LLC ("Marathon"), as well as other smaller acquisitions, for an aggregate purchase price of $1.02 billion. The Dendreon acquisition was completed via a "stalking horse bid" in a sales process conducted under the U.S. Bankruptcy Code for a purchase price of $415 million, net of cash received ($495 million less cash received of $80 million). The purchase price includes approximately $50 million in stock consideration. The assets acquired from Dendreon included the worldwide rights to the Provenge® product (an immunotherapy treatment designed to treat men with advanced prostate cancer). The assets acquired from Marathon comprised a portfolio of hospital products, including Nitropress®, Isuprel®, Opium Tincture, Pepcid®, Seconal® Sodium, Amytal® Sodium, and Iprivask® for an aggregate purchase price of $286 million (which is net of a $64 million assumed liability owed to a third party which is reflected in the table below).
	The business combinations completed during the first quarter of 2015 included contingent consideration arrangements with an aggregate acquisition date fair value of $90 million, primarily driven by the contingent consideration liability assumed as part of the acquisition of certain assets of Marathon (as described further below).
	The smaller acquisitions not specifically identified above are not material individually or in the aggregate. The Dendreon and Marathon acquisitions, as well as the other smaller acquisitions, are included in the aggregated amounts presented below.
	Assets Acquired and Liabilities Assumed
	These transactions have been accounted for as business combinations under the acquisition method of accounting. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the business combinations, in the aggregate, as of the applicable acquisition dates. Due to the timing of these acquisitions, these amounts are provisional and subject to change. The Company will finalize these amounts as it obtains the information necessary to complete the measurement processes. Any changes resulting from facts and circumstances that existed as of the acquisition dates may result in retrospective adjustments to the provisional amounts recognized at the acquisition dates. These changes could be significant. The Company will finalize these amounts no later than one year from the respective acquisition dates.
			Amounts
			Recognized as of
			Acquisition Dates
	Cash		$	80.2
	Accounts receivable(a)		23.9
	Inventories		104.3
	Other current assets		17.9
	Property, plant and equipment		71.3
	Identifiable intangible assets, excluding acquired IPR&D(b)		851.8
	Acquired IPR&D		1.5
	Other non-current assets		1.2
	Deferred tax asset, net		5.8
	Current liabilities(c)		(91.8		)
	Non-current liabilities(c)		(96.0		)
	Total identifiable net assets		970.1
	Goodwill(d)		50.8
	Total fair value of consideration transferred		$	1,020.90
	________________________
	(a)	The gross contractual amount of trade accounts receivable acquired was $24 million, which the Company expects will be fully collectible.
	(b)	The following table summarizes the provisional amounts and useful lives assigned to identifiable intangible assets:
			Weighted-		Amounts
			Average		Recognized as of
			Useful Lives		Acquisition Dates
			(Years)
	Product brands		7		$	580.4
	Product rights		3		42.6
	Partner relationships		8		7.8
	Technology/know-how		10		219
	Other		6		2
	Total identifiable intangible assets acquired		8		$	851.8
	(c)	As part of the Marathon acquisition, the Company assumed a contingent consideration liability related to potential payments for Isuprel® and Nitropress®, the amounts of which are dependent on the timing of generic entrants for these products. The fair value of the liability was determined using probability-weighted projected cash flows, with $41 million classified in Current liabilities and $46 million classified in Non-current liabilities in the table above.
	(d)	The goodwill relates primarily to the Marathon and other smaller acquisitions. Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Substantially all of the goodwill is expected to be deductible for tax purposes. The goodwill represents primarily the cost savings, operating synergies and other benefits expected to result from combining the operations with those of the Company.
	The provisional amount of goodwill has been allocated primarily to the Company’s Developed Markets segment.
	Acquisition-Related Costs
	The Company has incurred to date $8 million, in the aggregate, of transaction costs directly related to business combinations which closed in the first quarter of 2015, which includes expenditures for advisory, legal, valuation, accounting and other similar services. These costs have been expensed as acquisition-related costs.
	Revenue and Net Income
	The revenues of these business combinations for the period from the respective acquisition dates to March 31, 2015 were $168 million, in the aggregate, and net income was $43 million, in the aggregate. The net income includes the effects of the acquisition accounting adjustments and acquisition-related costs.
	(b) Business combinations in 2014 included the following:
	In the year ended December 31, 2014, the Company completed business combinations, which included the acquisition of the following businesses, for an aggregate purchase price of $1.35 billion. The aggregate purchase price included contingent consideration payment obligations with an aggregate acquisition date fair value of $94 million.
	•	On July 7, 2014, the Company acquired all of the outstanding common stock of PreCision Dermatology, Inc. (“PreCision”) for an aggregate purchase price of $453 million. Under the terms of the merger agreement, the Company may also pay contingent consideration of $25 million upon the achievement of a sales-based milestone. The fair value of this contingent consideration was determined to be nominal as of the acquisition date, based on the sales forecast. As of March 31, 2015, the assumptions used for determining the fair value of contingent consideration have not changed significantly from those used at the acquisition date. The Company recognized a post-combination expense of $20 million within Other (income) expense in the third quarter of 2014 related to the acceleration of unvested stock options for PreCision employees. In connection with the acquisition of PreCision, the Company was required by the Federal Trade Commission (“FTC”) to divest the rights to PreCision’s Tretin-X® (tretinoin) cream product and PreCision’s generic tretinoin gel and cream products. PreCision develops and markets a range of medical dermatology products, treating a number of topical disease states such as acne and atopic dermatitis with products such as Locoid® and Clindagel®.
	•	On January 23, 2014, the Company acquired all of the outstanding common stock of Solta Medical, Inc. (“Solta Medical”) for $293 million, which includes $2.92 per share in cash and $44 million for the repayment of Solta Medical’s long-term debt, including accrued interest. Solta Medical designs, develops, manufactures, and markets energy-based medical device systems for aesthetic applications, and its products include the Thermage CPT® system, the Fraxel® repair system, the Clear + Brilliant® system, and the Liposonix® system.
	•	During the year ended December 31, 2014, the Company completed other smaller acquisitions, including the consolidation of variable interest entities, which are not material individually or in the aggregate. These acquisitions are included in the aggregated amounts presented below.
	Assets Acquired and Liabilities Assumed
	These transactions have been accounted for as business combinations under the acquisition method of accounting. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the business combinations, in the aggregate, as of the applicable acquisition dates. The following recognized amounts related to the PreCision acquisition, as well as certain smaller acquisitions, are provisional and subject to change:
	•	amounts for intangible assets, property and equipment, inventories, receivables and other working capital adjustments pending finalization of the valuation;
	•	amounts for income tax assets and liabilities, pending finalization of estimates and assumptions in respect of certain tax aspects of the transaction; and
	•	amount of goodwill pending the completion of the valuation of the assets acquired and liabilities assumed.
	The Company will finalize these amounts as it obtains the information necessary to complete the measurement processes. Any changes resulting from facts and circumstances that existed as of the acquisition dates may result in retrospective adjustments to the provisional amounts recognized at the acquisition dates. These changes could be significant. The Company will finalize these amounts no later than one year from the respective acquisition dates.
			Amounts				Measurement				Amounts
			Recognized as of				Period				Recognized as of
			Acquisition Dates				Adjustments(a)				31-Mar-15
											(as adjusted)
	Cash and cash equivalents		$	33.6			$	1			$	34.6
	Accounts receivable(b)		87.7				(6.5		)		81.2
	Assets held for sale(c)		125.7				(0.6		)		125.1
	Inventories		170.4				(15.3		)		155.1
Other current assets		19.1				(1.1		)		18
Property, plant and equipment, net		58.5				(3.0		)		55.5
Identifiable intangible assets, excluding acquired IPR&D(d)		697.2				6.3				703.5
Acquired IPR&D(e)		65.8				(2.8		)		63
Other non-current assets		4				(2.1		)		1.9
Current liabilities		(152.0		)		(18.2		)		(170.2		)
Long-term debt, including current portion		(11.2		)		—				(11.2		)
Deferred income taxes, net		(116.0		)		36				(80.0		)
Other non-current liabilities		(13.4		)		(0.1		)		(13.5		)
Total identifiable net assets		969.4				(6.4		)		963
Noncontrolling interest		(15.0		)		0.2				(14.8		)
Goodwill(f)		410.4				(9.5		)		400.9
Total fair value of consideration transferred		$	1,364.80			$	(15.7	)		$	1,349.10
________________________
(a)	The measurement period adjustments primarily reflect: (i) a decrease in the net deferred tax liability primarily related to the PreCision and Solta Medical acquisitions and (ii) reductions in the estimated fair value of inventory for Solta Medical and other smaller acquisitions. The measurement period adjustments were made to reflect facts and circumstances existing as of the acquisition date, and did not result from intervening events subsequent to the acquisition date. These adjustments did not have a significant impact on the Company’s previously reported consolidated financial statements and, therefore, the Company has not retrospectively adjusted those financial statements.
(b)	The fair value of trade accounts receivable acquired was $81 million, with the gross contractual amount being $88 million, of which the Company expects that $7 million will be uncollectible.
(c)	Assets held for sale relate to the Tretin-X® product rights and the product rights for the generic tretinoin gel and cream products acquired in the PreCision acquisition, which were subsequently divested in the third quarter of 2014.
(d)	The following table summarizes the provisional amounts and useful lives assigned to identifiable intangible assets:
		Weighted-		Amounts				Measurement				Amounts
		Average		Recognized as of				Period				Recognized as of
		Useful Lives		Acquisition Dates				Adjustments				31-Mar-15
		(Years)										(as adjusted)
Product brands		10		$	506			$	8.3			$	514.3
Product rights		8		95.2				(3.3		)		91.9
Corporate brand		15		28.9				1.7				30.6
In-licensed products		9		1.5				(0.4		)		1.1
Partner relationships		9		37.5				—				37.5
Other		9		28.1				—				28.1
Total identifiable intangible assets acquired		10		$	697.2			$	6.3			$	703.5
(e)	The acquired IPR&D assets primarily relate to programs from smaller acquisitions. In addition, the Solta Medical acquisition includes a program for the development of a next generation Thermage® product.
(f)	The goodwill relates primarily to the PreCision and Solta Medical acquisitions. Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Substantially all of the goodwill is not expected to be deductible for tax purposes. The goodwill recorded from the PreCision and Solta Medical acquisitions represents the following:
•	cost savings, operating synergies and other benefits expected to result from combining the operations of PreCision and Solta Medical with those of the Company;
•	the Company’s expectation to develop and market new products and technology; and
•	intangible assets that do not qualify for separate recognition (for instance, PreCision’s and Solta Medical’s assembled workforces).
The provisional amount of goodwill from the PreCision acquisition has been allocated to the Company’s Developed Markets segment ($178 million). The amount of goodwill from the Solta Medical acquisition has been allocated to both the Company’s Developed Markets segment ($56 million) and Emerging Markets segment ($38 million).
Pro Forma Impact of Business Combinations
The following table presents unaudited pro forma consolidated results of operations for the three-month periods ended March 31, 2015 and 2014, as if the 2015 acquisitions had occurred as of January 1, 2014 and the 2014 acquisitions had occurred as of January 1, 2013.
	Three Months Ended
	March 31,
	2015				2014
Revenues	$	2,270.40			$	2,056.40
Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.	93.8				(73.9		)
Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:
Basic	$	0.28			$	(0.22	)
Diluted	$	0.27			$	(0.22	)
The increase in pro forma revenues in the three-month period ended March 31, 2015 as compared to the three-month period ended March 31, 2014 was primarily due to growth from the existing business, including the impact of recent product launches. These increases were partially offset by a negative foreign currency exchange impact and lower sales resulting from the July 2014 divestiture of facial aesthetic fillers and toxins.
The unaudited pro forma consolidated results of operations were prepared using the acquisition method of accounting and are based on the historical financial information of the Company and the acquired businesses described above. Except to the extent realized in the three-month period ended March 31, 2015, the unaudited pro forma information does not reflect any cost savings, operating synergies and other benefits that the Company may achieve as a result of these acquisitions, or the costs necessary to achieve these cost savings, operating synergies and other benefits. In addition, except to the extent recognized in the three-month period ended March 31, 2015, the unaudited pro forma information does not reflect the costs to integrate the operations of the Company with those of the acquired businesses.
The unaudited pro forma information is not necessarily indicative of what the Company’s consolidated results of operations actually would have been had the 2015 acquisitions and the 2014 acquisitions been completed on January 1, 2014 and January 1, 2013, respectively. In addition, the unaudited pro forma information does not purport to project the future results of operations of the Company. The unaudited pro forma information reflects primarily the following adjustments:
•	elimination of the historical intangible asset amortization expense of these acquisitions;
•	additional amortization expense related to the fair value of identifiable intangible assets acquired;
•	adjustments to depreciation expense related to fair value adjustments to property, plant and equipment acquired;
•	the exclusion from pro forma earnings in the three-month periods ended March 31, 2015 and 2014 of the acquisition accounting adjustments on these acquisitions’ inventories that were sold subsequent to the acquisition date of $24 million and $5 million for the three-month periods ended March 31, 2015 and 2014 and the acquisition-related costs incurred for these acquisitions, and the inclusion of those amounts in pro forma earnings for the corresponding comparative periods.
In addition, all of the above adjustments were adjusted for the applicable tax impact.

RESTRUCTURING_INTEGRATION_AND_

RESTRUCTURING, INTEGRATION AND OTHER COSTS	3 Months Ended
	Mar. 31, 2015
Restructuring and Related Activities [Abstract]
RESTRUCTURING, INTEGRATION AND OTHER COSTS	RESTRUCTURING, INTEGRATION AND OTHER COSTS
	In connection with the Bausch & Lomb Holdings Incorporated (“B&L”) acquisition (the "B&L Acquisition"), as well as other acquisitions, the Company has implemented cost-rationalization and integration initiatives to capture operating synergies and generate cost savings across the Company. These measures included:
	•	workforce reductions across the Company and other organizational changes;
	•	closing of duplicative facilities and other site rationalization actions company-wide, including research and development facilities, sales offices and corporate facilities;
	•	leveraging research and development spend; and
	•	procurement savings.
	B&L Acquisition-Related Cost-Rationalization and Integration Initiatives
	The Company estimates that it will incur total costs of approximately $600 million (excluding charges of $53 million described under the table below) in connection with these cost-rationalization and integration initiatives relating to the B&L Acquisition, which were substantially completed by the end of 2014. However, costs have been incurred in 2015 and additional costs may still be incurred later in the year. Since the acquisition date, total costs of $578 million (including $56 million related to cost-rationalization measures at a contact lens manufacturing plant in Waterford, Ireland, as described below) have been incurred through March 31, 2015, including (i) $311 million of restructuring expenses, (ii) $254 million of integration expenses, and (iii) $13 million of acquisition-related costs. The estimate of total costs to be incurred primarily includes: employee termination costs payable to approximately 3,000 employees of the Company and B&L who have been or will be terminated as a result of the B&L Acquisition; IPR&D termination costs related to the transfer to other parties of product-development programs that did not align with our research and development model; costs to consolidate or close facilities and relocate employees; and contract termination and lease cancellation costs.
	B&L Restructuring Costs
	The following table summarizes the major components of the restructuring costs incurred in connection with the B&L Acquisition since the acquisition date through March 31, 2015:
			Employee Termination Costs						IPR&D		Contract
									Termination		Termination,
									Costs		Facility Closure
			Severance and			Share-Based					and Other Costs			Total
			Related Benefits			Compensation(1)
	Balance, January 1, 2013		$	—		$	—		$	—	$	—		$	—
	Costs incurred and/or charged to expense		155.7			52.8			—		25.6			234.1
	Cash payments		(77.8		)	(52.8		)	—		(7.8		)	(138.4		)
	Non-cash adjustments		11.4			—			—		(6.8		)	4.6
	Balance, December 31, 2013		$	89.3		$	—		$	—	$	11		$	100.3
	Costs incurred and charged to expense		46			—			—		23.7			69.7
	Cash payments		(110.7		)	—			—		(24.9		)	(135.6		)
	Non-cash adjustments		(5.7		)	—			—		(5.4		)	(11.1		)
	Balance, December 31, 2014(2)		$	18.9		$	—		$	—	$	4.4		$	23.3
	Costs incurred and charged to expense		3			—			—		0.9			3.9
	Cash payments		(12.6		)	—			—		(1.3		)	(13.9		)
	Non-cash adjustments		(1.5		)	—			—		(1.2		)	(2.7		)
	Balance, March 31, 2015		$	7.8		$	—		$	—	$	2.8		$	10.6
	___________________________________
	-1	Relates to B&L’s previously cancelled performance-based options and the acceleration of unvested stock options for B&L employees as a result of the B&L Acquisition were recognized in Other (income) expense.
	-2	In the three-month period ended March 31, 2014, the Company recognized $29 million of restructuring charges and made payments of $54 million related to the B&L Acquisition.
	B&L Integration Costs
	As mentioned above, the Company has incurred $254 million of integration costs related to the B&L Acquisition since the acquisition date. In the three-month periods ended March 31, 2015 and 2014, the Company incurred $5 million and $69 million, respectively, of integration costs related to the B&L Acquisition, which related primarily to integration consulting, duplicate labor, transition service, and other costs. The Company made payments of $8 million and $57 million related to B&L integration costs during the three-month periods ended March 31, 2015 and 2014, respectively.
	In addition to the restructuring and integration costs described above, the Company has recognized $56 million of restructuring costs related to a contact lens manufacturing plant in Waterford, Ireland (the plant was acquired as part of the B&L Acquisition) since the acquisition date, of which a nominal amount was recognized in the three-month period ended March 31, 2015. These costs related to employee termination costs with respect to cost-rationalization measures. The Company made payments of $16 million in the three-month period ended March 31, 2015 with respect to this initiative.
	Other Restructuring and Integration-Related Costs (Excluding B&L)
	In the three-month period ended March 31, 2015, in addition to the restructuring and integration costs associated with the B&L Acquisition described above, the Company incurred an additional $46 million of other restructuring, integration-related and other costs. These costs included (i) $23 million of integration consulting, duplicate labor, transition service, and other costs, (ii) $21 million of severance costs, (iii) $1 million of facility closure costs, and (iv) $1 million of other costs. These costs primarily related to integration and restructuring costs for the Dendreon and other smaller acquisitions. The Company made payments of $27 million during the three-month period ended March 31, 2015 (in addition to the payments related to the B&L Acquisition described above).
	In the three-month period ended March 31, 2014, in addition to the restructuring and integration costs associated with the B&L Acquisition described above, the Company incurred an additional $35 million of other restructuring, integration-related and other costs. These costs included (i) $12 million of severance costs, (ii) $11 million of integration consulting, duplicate labor, transition service, and other costs, (iii) $8 million of facility closure costs, and (iv) $4 million of other costs. These costs primarily related to (i) integration and restructuring costs for other smaller acquisitions and (ii) intellectual property migration and the global consolidation of the Company’s manufacturing facilities. The Company made payments of $26 million during the three-month period ended March 31, 2014 (in addition to the payments related to the B&L Acquisition described above).

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS
	Fair value measurements are estimated based on valuation techniques and inputs categorized as follows:
	•	Level 1 — Quoted prices in active markets for identical assets or liabilities;
	•	Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
	•	Level 3 — Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.
	If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
	Assets and Liabilities Measured at Fair Value on a Recurring Basis
	The following fair value hierarchy table presents the components and classification of the Company’s financial assets and liabilities measured at fair value as of March 31, 2015 and December 31, 2014:
			As of March 31, 2015															As of December 31, 2014
			Carrying				Quoted			Significant				Significant				Carrying				Quoted			Significant		Significant
			Value				Prices			Other				Unobservable				Value				Prices			Other		Unobservable
							in Active			Observable				Inputs								in Active			Observable		Inputs
							Markets for			Inputs				(Level 3)								Markets for			Inputs		(Level 3)
							Identical			(Level 2)												Identical			(Level 2)
							Assets															Assets
							(Level 1)															(Level 1)
	Assets:
	Cash equivalents(1)		$	120.3			$	115		$	5.3			$	—			$	4.6			$	2.8		$	1.8	$	—
	Restricted cash and cash equivalents(2)		$	10,354.90			$	10,354.90		$	—			$	—			$	9.1			$	9.1		$	—	$	—
	Liabilities:
	Derivative financial instruments:
	Foreign exchange contracts(3)		$	(26.6	)		$	—		$	(26.6	)		$	—			$	—			$	—		$	—	$	—
	Acquisition-related contingent consideration		$	(385.2	)		$	—		$	—			$	(385.2	)		$	(308.8	)		$	—		$	—	$	(308.8	)
	___________________________________
	-1	Cash equivalents include highly liquid investments with an original maturity of three months or less at acquisition, primarily including money market funds, reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.
	-2	The restricted cash and cash equivalents is primarily invested in highly liquid money market funds, reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature. Refer to Note 8 titled "LONG-TERM DEBT" for additional information regarding the restricted cash and cash equivalents.
	-3	In March 2015, the Company entered into foreign currency forward-exchange contracts to sell €1.53 billion and buy U.S. Dollars in order to reduce its exposure to the variability in expected cash inflows attributable to the changes in foreign exchange rates related to the €1.50 billion aggregate principal amount and related interest of 4.50% senior unsecured notes due 2023 (the "Euro Notes") issued on March 27, 2015, the proceeds of which were used to finance the Salix Acquisition (see note 8 titled "LONG-TERM DEBT" for additional information). These derivative contracts are not designated as hedges for accounting purposes, and such contracts matured on April 1, 2015 (which coincides with the consummation of the Salix Acquisition). As of March 31, 2015, the Company recorded $27 million within Accrued and other current liabilities in the consolidated balance sheets representing the fair value of these derivatives (the fair value approximates the settlement amount), and a foreign exchange loss of $27 million was recognized in Foreign exchange and other in the consolidated income (loss) for the three-month period ended March 31, 2015.
	In addition to the above, the Company has time deposits valued at cost, which approximates fair value due to their short-term maturities. The carrying value of $25 million and $43 million as of March 31, 2015 and December 31, 2014, respectively, related to these investments is classified within Prepaid expenses and other current assets in the consolidated balance sheets. These investments are Level 2.
	There were no transfers between Level 1 and Level 2 during the three-month period ended March 31, 2015.
	Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3)
	The fair value measurement of contingent consideration obligations arising from business combinations is determined using unobservable (Level 3) inputs. These inputs include (i) the estimated amount and timing of projected cash flows; (ii) the probability of the achievement of the factor(s) on which the contingency is based; and (iii) the risk-adjusted discount rate used to present value the probability-weighted cash flows. Significant increases (decreases) in any of those inputs in isolation could result in a significantly lower (higher) fair value measurement.
	The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3) for the three-month period ended March 31, 2015:
		Balance,				Issuances(a)			Payments(b)				Net				Foreign				Release from Restricted Cash			Balance,
		January 1,											Unrealized				Exchange(d)							March 31,
		2015											Loss(c)											2015(e)
	Acquisition-related contingent consideration	$	(308.8	)		$	(90.2	)	$	14.5			$	(7.1	)		$	3.9			$	2.5		$	(385.2	)
	____________________________________
	(a)	Primarily relates to a contingent consideration liability assumed in the Marathon acquisition, as described in note 3 titled "BUSINESS COMBINATIONS".
	(b)	Primarily relates to payments of acquisition-related contingent consideration for the Elidel®/Xerese®/Zovirax® agreement entered into with Meda Pharma SARL in June 2011 (the "Elidel®/Xerese®/Zovirax® agreement").
	(c)	For the three months ended March 31, 2015, a net loss of $7 million was recognized as Acquisition-related contingent consideration in the consolidated statements of income (loss), primarily reflecting accretion for the time value of money for the Elidel®/Xerese®/Zovirax® agreement.
	(d)	Included in other comprehensive income (loss).
	(e)	For the three months ended March 31, 2015, there were no transfers into or out of Level 3.
	Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis
	There were no significant assets or liabilities that were re-measured at fair value on a non-recurring basis subsequent to initial recognition in the three-month period ended March 31, 2015.

INVENTORIES

INVENTORIES	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES
	The components of inventories as of March 31, 2015 and December 31, 2014 were as follows:
			As of		As of
			March 31,		December 31,
			2015		2014
	Raw materials(1)		$	239.1	$	191.1
	Work in process(1)		101.1		94.2
	Finished goods(1)		658.7		665.3
			998.9		950.6
	___________________________________
	-1	The components of inventories shown in the table above are presented net of allowance for obsolescence.

INTANGIBLE_ASSETS_AND_GOODWILL

INTANGIBLE ASSETS AND GOODWILL	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND GOODWILL	INTANGIBLE ASSETS AND GOODWILL
	Intangible Assets
	The major components of intangible assets as of March 31, 2015 and December 31, 2014 were as follows:
			As of March 31, 2015									As of December 31, 2014
			Gross			Accumulated			Net			Gross		Accumulated			Net
			Carrying			Amortization,			Carrying			Carrying		Amortization,			Carrying
			Amount			Including			Amount			Amount		Including			Amount
						Impairments								Impairments
	Finite-lived intangible assets:
	Product brands		$	10,691.40		$	(3,763.8	)	$	6,927.60		$	10,320.20	$	(3,579.8	)	$	6,740.40
	Corporate brands		352.7			(67.4		)	285.3			364.2		(65.2		)	299
	Product rights		3,248.20			(1,360.8		)	1,887.40			3,225.90		(1,263.8		)	1,962.10
	Partner relationships		203			(102.5		)	100.5			223.1		(107.5		)	115.6
	Technology and other		496.3			(131.6		)	364.7			275.5		(124.3		)	151.2
	Total finite-lived intangible assets		14,991.60			(5,426.1		)	9,565.50			14,408.90		(5,140.6		)	9,268.30
	Indefinite-lived intangible assets:
	Acquired IPR&D		291.6			—			291.6			290.1		—			290.1
	Corporate brand(1)		1,697.50			—			1,697.50			1,697.50		—			1,697.50
			$	16,980.70		$	(5,426.1	)	$	11,554.60		$	16,396.50	$	(5,140.6	)	$	11,255.90
	____________________________________
	-1	Represents the B&L corporate trademark, which has an indefinite useful life and is therefore not amortized.
	Estimated aggregate amortization expense, as of March 31, 2015, for each of the five succeeding years ending December 31 is as follows:
			2015			2016			2017			2018		2019
	Amortization expense(1)		$	1,466.40		$	1,379.50		$	1,317.20		$	1,184.10	$	1,043.60
	____________________________________
	-1	Estimated amortization expense shown in the table above does not include potential future impairments of finite-lived intangible assets, if any, nor does it include any amortization with respect to the Salix Acquisition which was completed on April 1, 2015.
	Goodwill
	The changes in the carrying amount of goodwill in the three-month period ended March 31, 2015 were as follows:
			Developed			Emerging			Total
			Markets			Markets
	Balance, January 1, 2015		$	7,115.00		$	2,231.40		$	9,346.40
	Additions(a)		41.4			9.4			50.8
	Adjustments(b)		4			0.6			4.6
	Foreign exchange and other		(161.2		)	(79.2		)	(240.4		)
	Balance, March 31, 2015		$	6,999.20		$	2,162.20		$	9,161.40
	____________________________________
	(a)	Primarily relates to the Marathon acquisition, as well as other smaller acquisitions (as described in note 3).
	(b)	Primarily reflects the impact of measurement period adjustments related to the PreCision acquisition.
	As described in note 3 titled "BUSINESS COMBINATIONS", the allocations of the goodwill balance associated with the certain acquisitions are provisional and subject to the completion of the valuation of the assets acquired and liabilities assumed.

LONGTERM_DEBT

LONG-TERM DEBT	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
LONG-TERM DEBT	LONG-TERM DEBT
	A summary of the Company’s consolidated long-term debt as of March 31, 2015 and December 31, 2014, respectively, is outlined in the table below:
			Maturity	As of			As of
			Date	March 31,			December 31,
				2015			2014
	Revolving Credit Facility(1)		April 2018	$	225		$	165
	Series A-1 Tranche A Term Loan Facility(1)		April 2016	139.1			139.6
	Series A-2 Tranche A Term Loan Facility(1)		Apr-16	135.3			135.7
	Series A-3 Tranche A Term Loan Facility(1)		Oct-18	1,877.30			1,637.90
	Series D-2 Tranche B Term Loan Facility(1)		Feb-19	1,084.10			1,089.70
	Series C-2 Tranche B Term Loan Facility(1)		Dec-19	834			838.3
	Series E-1 Tranche B Term Loan Facility(1)		Aug-20	2,529.50			2,544.90
	Senior Notes:
	6.88%		December 2018	—			497.7
	7.00%		October 2020	687.6			687.5
	6.75%		August 2021	650			650
	7.25%		July 2022	543.4			543.2
	6.38%		Oct-20	2,226.60			2,225.60
	6.75%		Aug-18	1,586.80			1,585.80
	7.50%		Jul-21	1,609.10			1,608.40
	5.63%		Dec-21	892.9			892.6
	5.50%		Mar-23	991.7			—
	5.38%		Mar-20	1,977.60			—
	5.88%		May-23	3,213.50			—
	4.50%(2)		May-23	1,591.50			—
	6.13%		Apr-25	3,213.50			—
	Other(3)		Various	12.2			12.7
				26,020.70			15,254.60
	Less current portion			(122.8		)	(0.9		)
	Total long-term debt			$	25,897.90		$	15,253.70
	____________________________________
	-1	Together, the “Senior Secured Credit Facilities” under the Company’s Third Amended and Restated Credit and Guaranty Agreement, as amended (the “Credit Agreement”).
	-2	Represents the U.S. dollar equivalent of Euro-denominated debt (discussed below).
	-3	Relates primarily to the debentures from B&L.
	The Company’s Senior Secured Credit Facilities and indentures related to its senior notes contain customary covenants, including, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company’s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates.
	The Company’s Senior Secured Credit Facilities also contain specified financial covenants (consisting of a secured leverage ratio and an interest coverage ratio), various customary affirmative covenants and specified events of default. The Company’s indentures also contain certain customary affirmative covenants and specified events of default.
	As of March 31, 2015, the Company was in compliance with all covenants related to the Company’s outstanding debt.
	The total fair value of the Company’s long-term debt, with carrying values of $26.02 billion and $15.25 billion at March 31, 2015 and December 31, 2014, was $26.93 billion and $15.78 billion, respectively. The fair value of the Company’s long-term debt is estimated using the quoted market prices for the same or similar debt issuances (Level 2).
	Senior Secured Credit Facilities
	On January 22, 2015, the Company and certain of its subsidiaries, as guarantors, entered into joinder agreements to allow for an increase in commitments under the Revolving Credit Facility to $1.50 billion and the issuance of $250 million in incremental term loans under the Series A-3 Tranche A Term Loan Facility. The Revolving Credit Facility and the Series A-3 Tranche A Term Loan Facility terms remained unchanged.
	On March 5, 2015, the Company entered into an amendment to the Credit Agreement to implement certain revisions in connection with the Salix Acquisition. The amendment, among other things, permitted the Salix Acquisition and the refinancing, repayment, termination and discharge of Salix's outstanding indebtedness, as well as the issuance of senior unsecured notes to be used to fund the Salix Acquisition (as described below). The amendment also modified the interest coverage ratio financial maintenance covenant applicable to the Company through March 31, 2016.
	Concurrently with the Salix Acquisition, the Company entered into joinders to the Credit Agreement to allow for the issuance of incremental term loans in an aggregate principal amount of $5.15 billion. See note 17 titled “SUBSEQUENT EVENTS” for additional information.
	For the three-month period ended March 31, 2015, the effective rate of interest on the Company’s borrowings was as follows: (i) 2.45% per annum under the Revolving Credit Facility, (ii) 2.39% per annum under the Series A-1 Tranche A Term Loan Facility, (iii) 2.38% per annum under both the Series A-2 Tranche A Term Loan Facility and the Series A-3 Tranche A Term Loan Facility, and (iv) 3.50% per annum under the Series D-2 Tranche B Term Loan Facility, the Series C-2 Tranche B Term Loan Facility, and the Series E-1 Tranche B Term Loan Facility.
	5.50% Senior Notes due 2023
	On January 30, 2015, the Company issued $1.00 billion aggregate principal amount of the 5.50% senior unsecured notes due 2023 ("2023 Notes") in a private placement. The 2023 Notes mature on March 1, 2023 and bear interest at the rate of 5.50% per annum, payable semi-annually in arrears, commencing on September 1, 2015. In connection with the issuance of the 2023 Notes, the Company incurred approximately $8 million in underwriting fees, which were recognized as debt issue discount and resulted in net proceeds of $992 million. The 2023 Notes are guaranteed by each of the Company’s subsidiaries that is a guarantor of the Company’s existing Senior Secured Credit Facilities.
	The net proceeds of the 2023 Notes offering were used to (i) redeem all of the outstanding 6.875% senior notes on February 17, 2015, as described below, (ii) repay amounts drawn under the Revolving Credit Facility, and (iii) for general corporate purposes.
	The indenture governing the terms of the 2023 Notes provides that at any time prior to March 1, 2018, the Company may redeem up to 40% of the aggregate principal amount of the 2023 Notes using the proceeds of certain equity offerings at a redemption price of 105.50% of the principal amount of the 2023 Notes, plus accrued and unpaid interest to the date of redemption. On or after March 1, 2018, the Company may redeem all or a portion of the 2023 Notes at the redemption prices applicable to the 2023 Notes, as set forth in the 2023 Notes indenture, plus accrued and unpaid interest to the date of redemption.
	If the Company experiences a change in control, the Company may be required to repurchase the 2023 Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the 2023 Notes repurchased, plus accrued and unpaid interest to, but excluding the applicable purchase date of the 2023 Notes.
	6.875% Senior Notes
	On February 17, 2015, Valeant redeemed $500 million of the outstanding principal amount of its 6.875% senior notes due December 2018 (the "December 2018 Notes") for $524 million, including a call premium of $17 million, plus accrued and unpaid interest, and satisfied and discharged the December 2018 Notes indenture. In connection with this transaction, the Company recognized a loss on extinguishment of debt of $20 million in the three-month period ended March 31, 2015.
	Senior Unsecured Notes
	On March 27, 2015, VRX Escrow Corp. (the "Issuer"), a newly formed wholly owned Canadian subsidiary of the Company, issued $2 billion aggregate principal amount of 5.375% senior unsecured notes due 2020 (the "2020 Notes"), $3.25 billion aggregate principal amount of 5.875% senior unsecured notes due 2023 (the "May 2023 Notes"), €1.50 billion aggregate principal amount of the Euro Notes, and $3.25 billion aggregate principal amount of 6.125% senior unsecured notes due 2025 (the "2025 Notes" and, together with the 2020 Notes, the May 2023 Notes and the Euro Notes, the "Notes") in a private placement. In connection with the issuance of the Notes, the Company incurred approximately $114 million in underwriting fees, in the aggregate, which were recognized as debt issue discount.
	In addition, the Issuer entered into an escrow and security agreement (the “Escrow Agreement”) dated as of March 27, 2015, with an escrow agent. Pursuant to the Escrow Agreement, the proceeds from the issuance of the Notes, together with cash sufficient to fund certain accrued and unpaid interest on the Notes, were deposited into escrow accounts and held as collateral security for the Issuer’s obligations until the consummation of the Salix Acquisition which occurred on April 1, 2015. As of March 31, 2015, the Company included $10.34 billion within Restricted cash and cash equivalents on the consolidated balance sheet.
	At the time of the closing of the Salix Acquisition in April 2015, (1) the Issuer was voluntarily liquidated and all of its obligations were assumed by, and all of its assets were distributed to, the Company, (2) the Company assumed all of the Issuer's obligations under the Notes and the related indenture and (3) the funds previously held in escrow were released to the Company and were used to finance the Salix Acquisition.
	The net proceeds from the issuance of the Notes, together with borrowings under the Company's incremental term loan facilities (described in note 17 titled “SUBSEQUENT EVENTS”), equity financing (described in note 11 titled “SHAREHOLDERS’ EQUITY”) and cash on hand, were used to fund (i) the transactions contemplated by the Merger Agreement, (ii) the refinancing, repayment, termination and discharge of Salix’s outstanding indebtedness (a portion of Salix’s indebtedness remains outstanding and will be repaid at a future date with proceeds from the incremental term loan facilities), and (iii) certain transaction expenses.
	The 2020 Notes will mature on March 15, 2020 and bear interest at the rate of 5.375% per annum, payable semi-annually in arrears, commencing on September 15, 2015. The May 2023 Notes and the Euro Notes will mature on May 15, 2023 and bear interest at the rate of 5.875% and 4.50% per annum, respectively, payable semi-annually in arrears, commencing on November 15, 2015. The 2025 Notes will mature on April 15, 2025 and bear interest at the rate of 6.125% per annum, payable semi-annually in arrears, commencing on October 15, 2015.
	The Notes are guaranteed by each of the Company’s subsidiaries that is a guarantor of the Company’s existing Senior Secured Credit Facilities.
	The indenture governing the terms of the Notes provides that the Company may redeem up to 40% of the aggregate principal amount of each series of the Notes using the proceeds of certain equity offerings, subject to specified conditions, at any time prior to (i) March 15, 2017 with respect to the 2020 Notes and at a redemption price of 105.375% of the principal amount of the 2020 Notes, plus accrued and unpaid interest to the date of the redemption, (ii) May 15, 2018 with respect to the May 2023 Notes and at a redemption price of 105.875% of the principal amount of the May 2023 Notes, plus accrued and unpaid interest to the date of the redemption, (iii) May 15, 2018 with respect to the Euro Notes and at a redemption price of 104.50% of the principal amount of the Euro Notes, plus accrued and unpaid interest to the date of the redemption, and (iv) April 15, 2018 with respect to the 2025 Notes and at a redemption price of 106.125% of the principal amount of the 2025 Notes, plus accrued and unpaid interest to the date of the redemption. On or after March 15, 2017, May 15, 2018, May 15, 2018, and April 15, 2020, the Company may redeem all or a portion of the 2020 Notes, the May 2023 Notes, the Euro Notes, and the 2025 Notes, respectively, at the redemption prices applicable to each series of the Notes, as set forth in the indenture.
	If the Company experiences a change in control, the Company may be required to repurchase the Notes, as applicable, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the applicable series of the Notes repurchased, plus accrued and unpaid interest to, but excluding the applicable purchase date of such series of the Notes.
	Commitment Letter
	In connection with the Salix Acquisition, the Company entered into a commitment letter dated as of February 20, 2015 (as amended and restated as of March 8, 2015, the “Commitment Letter”), with a syndicate of banks, led by Deutsche Bank and HSBC. Pursuant to the Commitment Letter, commitment parties committed to provide (i) incremental term loans pursuant to the Credit Agreement of up to $5.55 billion and (ii) senior unsecured increasing rate bridge loans under a new senior unsecured bridge facility of up to $9.60 billion. Subsequently, the Company obtained $15.25 billion in debt financing comprised of a combination of the incremental term loan facilities under the Company's existing Credit Agreement in an aggregate principal amount of $5.15 billion (of which $4.15 billion of tranche B term loans were fully drawn in April 2015, and $1.00 billion of tranche A term loans will be borrowed at a future date) and the issuance of the Notes in the U.S. dollar equivalent aggregate principal amount of approximately $10.1 billion, as described above. In the first quarter of 2015, the Company expensed $72 million of financing costs associated with the Commitment Letter to Interest expense in the consolidated statement of income (loss).
	In addition, on March 27, 2015, the Company issued new equity of approximately $1.45 billion to fund the Salix Acquisition (see note 11 titled “SHAREHOLDERS’ EQUITY” for additional information).

SHAREBASED_COMPENSATION

SHARE-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
SHARE-BASED COMPENSATION	SHARE-BASED COMPENSATION
	The following table summarizes the components and classification of share-based compensation expense related to stock options and restricted share units (“RSUs”) for the three-month periods ended March 31, 2015 and 2014:
		Three Months Ended
		March 31,
		2015		2014
	Stock options	$	3.9	$	5.1
	RSUs	31.1		19.7
	Share-based compensation expense	$	35	$	24.8
	Research and development expenses	$	1.5	$	1.4
	Selling, general and administrative expenses	33.5		23.4
	Share-based compensation expense	$	35	$	24.8
	In the three-month periods ended March 31, 2015 and 2014, the Company granted approximately 72,000 stock options with a weighted-average exercise price of $192.62 per option and approximately 72,000 stock options with a weighted-average exercise price of $144.86 per option, respectively. The weighted-average fair values of all stock options granted to employees in the three-month periods ended March 31, 2015 and 2014 were $63.11 and $53.29, respectively.
	In the three-month periods ended March 31, 2015 and 2014, the Company granted approximately 5,000 time-based RSUs with a weighted-average grant date fair value of $196.71 per RSU and approximately 60,000 time-based RSUs with a weighted-average grant date fair value of $137.66 per RSU, respectively.
	In the three-month periods ended March 31, 2015 and 2014, the Company granted approximately 600,000 performance-based RSUs with a weighted-average grant date fair value of $307.21 per RSU and approximately 99,000 performance-based RSUs with a weighted-average grant date fair value of $248.97 per RSU, respectively.
	As of March 31, 2015, the total remaining unrecognized compensation expense related to non-vested stock options, time-based RSUs and performance-based RSUs amounted to $335 million, in the aggregate, which will be amortized over a weighted-average period of 3.92 years.

PENSION_AND_POSTRETIREMENT_EMP

PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS	3 Months Ended
	Mar. 31, 2015
Compensation and Retirement Disclosure [Abstract]
PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS	PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS
	The Company sponsors defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers certain U.S. employees and employees in certain other countries.
	Net Periodic (Benefit) Cost
	The following table provides the components of net periodic (benefit) cost for the Company’s defined benefit pension plans and postretirement benefit plan for the three-month periods ended March 31, 2015 and 2014:
		Pension Benefit Plans												Postretirement
														Benefit
		U.S. Plan						Non-U.S. Plans						Plan
		Three Months Ended March 31,
		2015			2014			2015			2014			2015			2014
	Service cost	$	0.4		$	0.1		$	0.8		$	1		$	0.5		$	0.4
	Interest cost	2.4			2.7			1.6			2.2			0.5			0.6
	Expected return on plan assets	(3.6		)	(3.7		)	(2.0		)	(2.0		)	(0.1		)	(0.1		)
	Amortization of prior service credit	—			—			(0.1		)	—			(0.6		)	(0.6		)
	Amortization of net loss	—			—			0.4			—			—			—
	Net periodic (benefit) cost	$	(0.8	)	$	(0.9	)	$	0.7		$	1.2		$	0.3		$	0.3
	During the three-month period ended March 31, 2015, the Company contributed $2 million and $1 million to the U.S. and Non-U.S. pension benefit plans, respectively. In 2015, the Company expects to contribute $10 million and $7 million to the U.S. and Non-U.S. pension benefit plans, respectively, inclusive of amounts contributed to the plans during the three-month period ended March 31, 2015.

SHAREHOLDERS_EQUITY

SHAREHOLDERS' EQUITY	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
SHAREHOLDERS' EQUITY	SHAREHOLDERS’ EQUITY
		Valeant Pharmaceuticals International, Inc. Shareholders
		Common Shares			Additional			Accumulated			Accumulated			Valeant			Noncontrolling			Total
					Paid-In			Deficit			Other			Pharmaceuticals			Interest			Equity
					Capital						Comprehensive			International, Inc.
											Loss			Shareholders’
		Shares	Amount											Equity
	Balance, January 1, 2014	333	$	8,301.20	$	228.8		$	(3,278.5	)	$	(132.8	)	$	5,118.70		$	114.6		$	5,233.30
	Common shares issued under share-based compensation plans	0.5	15		(11.5		)	—			—			3.5			—			3.5
	Share-based compensation	—	—		24.8			—			—			24.8			—			24.8
	Employee withholding taxes related to share-based awards	—	—		(27.7		)	—			—			(27.7		)	—			(27.7		)
	Tax benefits from stock options exercised	—	—		1.2			—			—			1.2			—			1.2
	Acquisition of noncontrolling interest	—	—		(1.1		)	—			—			(1.1		)	(2.2		)	(3.3		)
		333.5	8,316.20		214.5			(3,278.5		)	(132.8		)	5,119.40			112.4			5,231.80
	Comprehensive loss:
	Net loss (income)	—	—		—			(22.6		)	—			(22.6		)	2.3			(20.3		)
	Other comprehensive loss	—	—		—			—			(7.2		)	(7.2		)	(0.8		)	(8.0		)
	Total comprehensive loss													(29.8		)	1.5			(28.3		)
	Balance, March 31, 2014	333.5	$	8,316.20	$	214.5		$	(3,301.1	)	$	(140.0	)	$	5,089.60		$	113.9		$	5,203.50
	Balance, January 1, 2015	334.4	$	8,349.20	$	243.9		$	(2,365.0	)	$	(915.9	)	$	5,312.20		$	122.3		$	5,434.50
	Issuance of common stock (see below)	7.3	1,431.90		—			—			—			1,431.90			—			1,431.90
	Common shares issued under share-based compensation plans	0.6	29.2		(14.7		)	—			—			14.5			—			14.5
	Share-based compensation	—	—		35			—			—			35			—			35
	Employee withholding taxes related to share-based awards	—	—		(21.2		)	—			—			(21.2		)	—			(21.2		)
	Tax benefits from stock options exercised	—	—		17.9			—			—			17.9			—			17.9
		342.3	9,810.30		260.9			(2,365.0		)	(915.9		)	6,790.30			122.3			6,912.60
	Comprehensive loss:
	Net income (loss)	—	—		—			73.7			—			73.7			0.8			74.5
	Other comprehensive loss	—	—		—			—			(411.7		)	(411.7		)	(0.2		)	(411.9		)
	Total comprehensive loss													(338.0		)	0.6			(337.4		)
	Balance, March 31, 2015	342.3	$	9,810.30	$	260.9		$	(2,291.3	)	$	(1,327.6	)	$	6,452.30		$	122.9		$	6,575.20
	____________________________________
	On March 27, 2015, the Company completed, pursuant to an Underwriting Agreement dated March 17, 2015 with Deutsche Bank Securities Inc. on behalf of several underwriters, a registered offering in the United States of 7,286,432 of its common shares, no par value, at a price of $199.00 per common share, for aggregate gross proceeds of approximately $1.45 billion. In connection with the issuance of these new common shares, the Company incurred approximately $18 million of issuance costs, which has been reflected as reduction to the gross proceeds from the equity issuance. The proceeds of this offering were used to fund the Salix Acquisition. The Company granted the underwriters an option to purchase additional common shares equal to up to 15% of the common shares initially issued in the offering. This option was not exercised by the underwriters.

ACCUMULATED_OTHER_COMPREHENSIV

ACCUMULATED OTHER COMPREHENSIVE LOSS	3 Months Ended
	Mar. 31, 2015
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
ACCUMULATED OTHER COMPREHENSIVE LOSS	ACCUMULATED OTHER COMPREHENSIVE LOSS
	The components of accumulated other comprehensive loss as of March 31, 2015 and 2014, were as follows:
			Foreign			Pension			Total
			Currency			Adjustment
			Translation
			Adjustment
	Balance, January 1, 2014		$	(170.3	)	$	37.5		$	(132.8	)
	Foreign currency translation adjustment		(6.6		)	—			(6.6		)
	Pension adjustment(1)		—			(0.6		)	(0.6		)
	Balance, March 31, 2014		$	(176.9	)	$	36.9		$	(140.0	)
	Balance, January 1, 2015		$	(886.5	)	$	(29.4	)	$	(915.9	)
	Foreign currency translation adjustment		(411.3		)	—			(411.3		)
	Pension adjustment(1)		—			(0.4		)	(0.4		)
	Balance, March 31, 2015		$	(1,297.8	)	$	(29.8	)	$	(1,327.6	)
	____________________________________
	-1	Reflects changes in defined benefit obligations and related plan assets of the Company’s defined benefit pension plans and the U.S. postretirement benefit plan (refer to note 10 titled "PENSION AN POSTRETIREMENT EMPLOYEE BENEFIT PLANS").
	Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company’s operations having a functional currency other than the U.S. dollar. Income taxes allocated to reclassification adjustments were not material.

INCOME_TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES
	In the three-month period ended March 31, 2015, the Company recognized an income tax expense of $81 million, comprised of $80 million related to the expected tax expense in tax jurisdictions outside of Canada and an income tax expense of $1 million related to Canadian income taxes. In the three-month period ended March 31, 2015, the Company’s effective tax rate was different from the Company’s statutory Canadian tax rate due to tax expense generated from the Company’s annualized mix of earnings by jurisdiction.
	The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. The valuation allowance against deferred tax assets is estimated to be $940 million as of March 31, 2015 and was $859 million as of December 31, 2014. The Company will continue to assess this amount for appropriateness on a go-forward basis associated with the deferred tax assets previously established.
	As of March 31, 2015, the Company had $345 million of unrecognized tax benefits, which included $40 million relating to interest and penalties. Of the total unrecognized tax benefits, $106 million would reduce the Company’s effective tax rate, if recognized. The Company anticipates that a minimal amount of unrecognized tax benefits may be resolved within the next 12 months.
	The Company’s policy is to recognize interest and penalties related to income tax matters in income tax expense. As of March 31, 2015, the Company had accrued $33 million for interest and $7 million for penalties.
	The Company is currently under examination by the Canada Revenue Agency for three separate cycles: (a) years 2005 to 2006, (b) 2007 through 2009, and (c) 2010 through 2011. In February 2013, the Company received a proposed audit adjustment for the years 2005 through 2007. The Company disagrees with the adjustments and has filed a Notice of Objection. The total proposed adjustment would result in a loss of tax attributes which are subject to a full valuation allowance and would not result in material change to the provision for income taxes.
	The Company’s U.S. consolidated federal income tax return for the 2011 and 2012 tax years is currently under examination by the Internal Revenue Service. The Company remains under examination for various state tax audits in the U.S. for years 2002 to 2013. In addition, certain affiliates of the Company in other regions outside of Canada and the U.S. are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's financial statements.

EARNINGS_LOSS_PER_SHARE

EARNINGS (LOSS) PER SHARE	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER SHARE	EARNINGS (LOSS) PER SHARE
	Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc. for the three-month periods ended March 31, 2015 and 2014 were calculated as follows:
		Three Months Ended
		March 31,
		2015		2014
	Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.	$	73.7	$	(22.6	)
	Basic weighted-average number of common shares outstanding	336.8		334.9
	Diluted effect of stock options, RSUs and other(a)	6.6		—
	Diluted weighted-average number of common shares outstanding	343.4		334.9
	Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:
	Basic	$	0.22	$	(0.07	)
	Diluted	$	0.21	$	(0.07	)
	____________________________________
	(a)	In the three-month period ended March 31, 2014, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been as follows:
			Three Months Ended
			March 31,
			2014
	Basic weighted-average number of common shares outstanding		334.9
	Dilutive effect of stock options and RSUs		6.6
	Diluted weighted-average number of common shares outstanding		341.5
	In the three-month periods ended March 31, 2015 and 2014, stock options to purchase approximately 143,000 and 741,000 common shares of the Company, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method.

LEGAL_PROCEEDINGS

LEGAL PROCEEDINGS	3 Months Ended
	Mar. 31, 2015
Loss Contingency, Information about Litigation Matters [Abstract]
LEGAL PROCEEDINGS	LEGAL PROCEEDINGS
	From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described below.
	Unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company’s business, financial condition and results of operations, and could cause the market value of its common shares to decline.
	Governmental and Regulatory Inquiries
	Legacy Biovail Matters
	On May 16, 2008, Biovail Pharmaceuticals, Inc. (“BPI”), the Company’s former subsidiary, entered into a written plea agreement with the U.S. Attorney’s Office (“USAO”) for the District of Massachusetts whereby it agreed to plead guilty to violating the U.S. Anti-Kickback Statute and pay a fine of $22 million.
	In addition, on May 16, 2008, the Company entered into a non-prosecution agreement with the USAO whereby the USAO agreed to decline prosecution of Biovail Corporation (“Biovail”) in exchange for continuing cooperation and a civil settlement agreement and pay a civil penalty of $2 million. A hearing before the U.S. District Court in Boston took place on September 14, 2009 and the plea was approved.
	In addition, as part of the overall settlement, Biovail entered into a Corporate Integrity Agreement (“CIA”) with the Office of the Inspector General and the Department of Health and Human Services on September 11, 2009. The CIA requires the Company to have a compliance program in place and to undertake a set of defined corporate integrity obligations for a five-year term. The CIA also includes requirements for an annual independent review of these obligations. Pursuant to the terms of the CIA, the Company expects the requirements contained in the CIA to terminate by the end of the second quarter of 2015. Failure to comply with the obligations under the CIA could result in financial penalties.
	Civil Investigative Demand from the U.S. Federal Trade Commission
	On May 2, 2012, Medicis Pharmaceutical Corporation ("Medicis") received a civil investigative demand from the FTC requiring that Medicis provide to the FTC information and documents relating to various settlement and other agreements with makers of generic SOLODYN® products following patent infringement claims and litigation, each of which was previously filed with the FTC and the Antitrust Division of the Department of Justice, and other efforts principally relating to SOLODYN®. On June 7, 2013, Medicis received an additional civil investigative demand relating to such settlements, agreements and efforts. Medicis is cooperating with this investigative process. If, at the conclusion of this process, the FTC believes that any of the agreements or efforts violates antitrust laws, it could challenge Medicis through a civil administrative or judicial proceeding. If the FTC ultimately challenges the agreements, we would expect to vigorously defend any such action.
	Subpoenas from the New York Office of Inspector General for the U.S. Department of Health and Human Services
	On June 29, 2011, B&L received a subpoena from the New York Office of Inspector General for the U.S. Department of Health and Human Services regarding payments and communications between B&L and medical professionals related to its pharmaceutical products Lotemax® and Besivance®. The government has indicated that the subpoena was issued in connection with a civil investigation, and B&L is cooperating fully with the government’s investigation. B&L has heard of no additional activity at this time, and whether the government’s investigation is ongoing or will result in further requests for information is unknown. B&L and the Company will continue to work with the Office of Inspector General regarding the scope of the subpoena and any additional specific information that may be requested.
	ISTA Settlement with Department of Justice
	On or about May 24, 2013 (prior to the Company’s acquisition of B&L in August 2013), B&L’s subsidiary, ISTA Pharmaceuticals, Inc. (“ISTA”), reached agreement with the U.S. government to resolve and conclude civil and criminal allegations against ISTA.  The settlement involved conduct by ISTA that occurred between January 2006 and March 2011, prior to B&L’s acquisition of ISTA in June 2012. B&L was aware of the government investigation prior to its acquisition, and fully cooperated with the government to resolve the matter.  In connection with the settlement, ISTA pled guilty to certain charges and paid approximately $34 million in civil and criminal fines, including interest and attorney’s fees. In addition, B&L agreed to maintain a specified compliance and ethics program and to annually certify compliance with this requirement to the Department of Justice for a period of three years. Failure to comply with the requirements of the settlement could result in fines.
	Securities
	Allergan Securities Litigation
	On August 1, 2014, Allergan Inc. ("Allergan") commenced the federal securities litigation in the U.S. District Court for the Central District of California against the Company, Valeant, Valeant’s subsidiary AGMS Inc. (“AGMS”), Pershing Square Capital Management, L.P. ("Pershing Square"), PS Management, GP, LLC, PS Fund 1, LLC (“PS Fund 1”) and William A. Ackman (Allergan, Inc. et al. v. Valeant Pharmaceuticals International, Inc., et al., Case No. 14-cv-01214-DOC). The lawsuit alleged violations of Sections 13(d), 14(a), 14(e) and 20A of the Exchange Act and rules promulgated by the SEC under those Sections. On August 19, 2014, the Company, Valeant, AGMS, PS Fund 1 and William A. Ackman filed Counterclaims against Allergan and the members of the Allergan Board of Directors alleging violations of Sections 14(a), 14(e) and 20A of the Exchange Act and rules promulgated by the SEC under those Sections. On November 4, 2014, the Court denied in part and granted in part a motion filed by plaintiffs seeking a preliminary injunction. The Court directed the defendants to make certain additional disclosures, and otherwise denied the motion. On January 28, 2015, the plaintiffs filed an amended complaint, alleging that all defendants violated Section 14(e) of the Exchange Act and SEC rules under that section. The amended complaint also asserted violations of Sections 13(d) and Schedule 13D thereunder and Section 20A of the Exchange Act against Pershing Square, PS Management, GP, LLC, PS Fund 1 and William A. Ackman. On April 9, 2015, the parties filed a stipulation providing for the voluntary dismissal of all claims.
	Allergan Shareholder Class Action
	On December 16, 2014, Anthony Basile, filed a putative class action lawsuit against the Company, Valeant, AGMS, Pershing Square, PS Management, GP, LLC, PS Fund 1 and William A. Ackman in the U.S. District Court for the Central District of California (Basile v. Valeant Pharmaceuticals International, Inc., et al., Case No. 14-cv-02004-DOC). The complaint alleges claims on behalf of a putative class of purchasers of Allergan securities between February 25, 2014 and April 21, 2014, against all defendants asserting violations of Sections 14(e) of the Exchange Act and rules promulgated by the SEC thereunder. The complaint also alleges violations of Section 20A of the Exchange Act against Pershing Square, PS Management, GP, LLC, PS Fund 1 and William A. Ackman. The complaint seeks, among other relief, money damages, equitable relief, and attorneys’ fees and costs. Defendants have not yet responded to the Complaint. The Company is reviewing these claims and intends to vigorously defend these matters.
	Salix Shareholder Class Actions
	Following the announcement of the execution of the Merger Agreement with Salix, six purported stockholder class actions were filed challenging the Salix Acquisition. All of the actions were filed in the Delaware Court of Chancery, and alleged claims against some or all of the board of directors of Salix (the “Salix Board”), the Company, Salix, Valeant and Sun Merger Sub, Inc. (“Sun Merger Sub”). On March 17, 2015, the Court consolidated the actions under the caption In re Salix Pharmaceuticals Shareholder Litigation (Court No. 10721-CB), and designated the complaint in one action to be the operative complaint. The operative complaint alleges generally that the members of the Salix Board breached their fiduciary duties to stockholders and that the other defendants aided and abetted such breaches, by seeking to sell Salix through an inadequate sale process and for inadequate consideration and by agreeing to allegedly preclusive deal protections. The complaint also alleges that the Form 14d-9 filed by Salix in connection with the Salix Acquisition contained inaccurate or materially misleading information about, among other things, the Salix Acquisition and the sales process leading up to the Merger Agreement. The complaint seeks, among other things, injunctive relief, including enjoining the proposed transaction, and unspecified attorneys’ and other fees and costs. On April 1, 2015, the defendants filed motions to dismiss the action. Those motions remain pending. The Company is vigorously defending this matter.
	Antitrust
	Solodyn® Antitrust Class Actions
	On July 22, 2013, United Food and Commercial Workers Local 1776 & Participating Employers Health and Welfare Fund, filed a civil antitrust class action complaint in the United States District Court for the Eastern District of Pennsylvania, Case No. 2:13-CV-04235-JCJ, against Medicis, the Company and various manufacturers of generic forms of Solodyn®, alleging that the defendants engaged in an anticompetitive scheme to exclude competition from the market for minocycline hydrochloride extended release tablets, a prescription drug for the treatment of acne marketed by Medicis under the brand name, Solodyn®.  The plaintiff further alleges that the defendants orchestrated a scheme to improperly restrain trade, and maintain, extend and abuse Medicis’ alleged monopoly power in the market for minocycline hydrochloride extended release tablets to the detriment of plaintiff and the putative class of end-payor purchasers it seeks to represent, causing them to pay overcharges.  Plaintiff alleges violations of Sections 1 and 2 of the Sherman Act, 15 U.S.C. §§ 1, 2, and of various state antitrust and consumer protection laws, and further alleges that defendants have been unjustly enriched through their alleged conduct. Plaintiff seeks declaratory and injunctive relief and, where applicable, treble, multiple, punitive and/or other damages, including attorneys’ fees.  Additional class action complaints making similar allegations against all defendants, including Medicis and the Company have been filed in various courts by other private plaintiffs purporting to represent certain classes of similarly-situated direct or end-payor purchasers of Solodyn® (Rochester Drug Co-Operative, Inc., Case No. 2:13-CV-04270-JCJ (E.D. Pa. filed July 23, 2013); Local 274 Health & Welfare Fund, Case No. 2:13-CV-4642-JCJ (E.D.Pa. filed Aug. 9, 2013); Sheet Metal Workers Local No. 25 Health & Welfare Fund, Case No. 2:13-CV-4659-JCJ (E.D. Pa. filed Aug. 8, 2013); Fraternal Order of Police, Fort Lauderdale Lodge 31, Insurance Trust Fund, Case No. 2:13-CV-5021-JCJ (E.D. Pa. filed Aug. 27, 2013); Heather Morgan, Case No. 2:13-CV-05097 (E.D. Pa. filed Aug. 29, 2013); Plumbers & Pipefitters Local 176 Health & Welfare Trust Fund, Case No. 2:13-CV-05105 (E.D. Pa. filed Aug. 30, 2013); Ahold USA, Inc., Case No. 1:13-cv-12225 (D. Mass. filed Sept. 9, 2013); City of Providence, Rhode Island, Case No. 2:13-cv-01952 (D. Ariz. filed Sept. 24, 2013); International Union of Operating Engineers Stationary Engineers Local 39 Health & Welfare Trust Fund, Case No. 1:13-cv-12435 (D. Mass. filed Oct. 2, 2013); Painters District Council No. 30 Health and Welfare Fund et al., Case No. 1:13-cv-12517 (D. Mass. filed Oct. 7, 2013); Man-U Service Contract Trust Fund, Case No. 13-cv-06266-JCJ (E.D. Pa. filed Oct. 25, 2013)).  On August 29, 2013, International Union of Operating Engineers Local 132 Health and Welfare Fund voluntarily dismissed the class action complaint it had originally filed on August 1, 2013, in the United States District Court for the Northern District of California, and on August 30, 2013, re-filed its class action complaint in the United States District Court for the Eastern District of Pennsylvania (Case No. 2:13-cv-05108). The International Union of Operating Engineers Local 132 Health and Welfare Fund complaint makes similar allegations against all defendants, including Medicis and the Company, and seeks similar relief, to the other end-payor plaintiff complaints.  On February 25, 2014, on a motion by Medicis and the Company, the Judicial Panel for Multidistrict Litigation (“JPML”) ordered that the cases pending outside the District of Massachusetts be transferred to the District of Massachusetts, with the consent of that court, for coordinated or consolidated pretrial proceedings with the actions already pending in that district.  The Multi-District Litigation (“MDL”), captioned In re Solodyn (Minocycline Hydrochloride) Antitrust Litigation, Case No. 1:14-md-02503-DJC, is now pending before U.S. District Judge Denise Casper.  Two additional end-payor actions have been filed in the District of Massachusetts since the February 25th centralization order:  Allied Services Division Welfare Fund, Case No. 1:14-cv-10786 (D. Mass. filed Mar. 14, 2014); and NECA-IBEW Welfare Trust Fund, Case No. 1:14-cv-11015 (D. Mass. filed Mar. 19, 2014).  These cases have been included in the pending MDL.  On September 12, 2014, the Direct Purchaser Plaintiffs and the End-Payor Plaintiffs each filed a consolidated amended class action complaint. The Direct Purchaser Plaintiffs, with the Defendants’ consent, subsequently filed a corrected amended complaint on September 22, 2014. On November 24, 2014, the Defendants jointly moved to dismiss the Direct Purchaser Plaintiffs’ and the End Payor Plaintiffs’ complaints.  Oral argument on the Defendants’ motion was held on March 12, 2015 and a decision is currently pending.  On March 26, 2015, and on April 6, 2015, two additional non-class action complaints were filed against Medicis in the Middle District of Pennsylvania by purported direct purchasers of Solodyn, making similar allegations and seeking similar relief to that sought in the other direct purchaser plaintiff complaints (Walgreen Co., et al. v. Medicis Pharmaceutical Corp.. No. 1:15-cv-00611-YK (M.D. Pa. filed March 26, 2015); Rite Aid Corp., et al. v. Medicis Pharmaceutical Corp., No. 1:15-cv-00673-YK (M.D. Pa. filed April 6, 2015)). On April 8, 2015, the JPML transferred the Walgreen complaint to the District of Massachusetts, where it is now included in the MDL. The Company intends to vigorously defend these actions.
	Intellectual Property
	AntiGrippin® Litigation
	Two suits have been brought against the Company’s subsidiary, Natur Produkt International, JSC ("Natur Produkt") seeking lost profits in connection with the registration by Natur Produkt of its AntiGrippin® trademark. The plaintiffs in these matters allege that Natur Produkt violated Russian competition law by preventing plaintiffs from producing and marketing their products under certain brand names. The first matter (Case No. A-56-23056/2013, Arbitration Court of St. Petersburg) was accepted for proceedings on June 24, 2013 and a hearing was held on November 28, 2013. In a decision dated December 4, 2013, the court found in favor of the plaintiff (AnviLab) and awarded the plaintiff lost profits in the amount of approximately RUR 1.66 billion (being approximately $50 million at the December 4, 2013 decision date). This charge was recognized in the fourth quarter of 2013 in Other (income) expense in the consolidated statements of income (loss). Natur Produkt appealed this decision, and a hearing in the appeal proceeding was held on March 16, 2014. The appeal court found in favor of Natur Produkt and dismissed the plaintiff’s claim in full. Following this decision, the Company concluded that the potential loss was no longer probable, and therefore the reserve was reversed in the first quarter of 2014 in Other (income) expense in the consolidated statements of income (loss). Anvilab appealed the appeal court’s decision to the cassation court. On June 19, 2014, the cassation court resolved that the matter is within the jurisdiction of the Intellectual Property (IP) court in this instance. The hearing before the IP court was held on July 30, 2014 and August 1, 2014. The IP court found in favor of the plaintiff and ruled to send the case for the second review to the court of the first instance, indicating that the court of the first instance should decide on the amount of damages suffered by Anvilab. Natur Produkt appealed the decision of the IP Court to the Supreme Court on September 15, 2014, but, on October 22, 2014, the Supreme Court denied that appeal and the matter was sent back to the court of first instance for the second review. The court of first instance appointed an expert to provide a report on the claimed lost profit amount, which was provided on or about March 10, 2015. Hearings before the court of first instance in this matter were held on March 12, 2015 and April 9, 2015. Following the April 9, 2015 hearing, the court of first instance ruled in favor of the plaintiff and awarded the plaintiff lost profits in the amount of approximately RUR 1.66 billion (being approximately $31 million as of the April 9, 2015 decision date). Natur Produkt intends to appeal this decision, both as to the merits and the quantum of damages, to the appeal court. At this time, the Company cannot predict the outcome of this appeal. Accordingly, the Company has not recognized a reserve as of March 31, 2015.
	Natur Produkt was served with a claim in the second matter (Case No. A-56-38592/2013, Arbitration Court of St. Petersburg) on July 16, 2013 by the plaintiff in that matter (ZAO Tsentr Vnedreniya PROTEK (“Protek”)). A hearing was held in this matter on September 29, 2013 and, on October 18, 2013, the court found in favor of Natur Produkt. Protek filed an appeal of the decision on November 26, 2013. A hearing in the appeal proceeding was held on January 30, 2014 and the appeal court also found in favor of Natur Produkt. Protek appealed that decision to the cassation court (Case No. A-56-38592/2013) and, on July 7, 2014, the cassation court also found in favor of Natur Produkt. Protek did not exercise its right to appeal the cassation court decision to the Supreme Court.
	Patent Litigation/Paragraph IV Matters
	The Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States, including as arising from claims filed by the Company in connection with Notices of Paragraph IV Certification received from third parties respecting their pending ANDA applications for generic versions of certain products sold by or on behalf of the Company, including Prolensa®, Apriso® and Uceris®, or other similar suits. These matters are proceeding in the ordinary course.
	General Civil Actions
	Afexa Class Action
	On March 9, 2012, a Notice of Civil Claim was filed in the Supreme Court of British Columbia which seeks an order certifying a proposed class proceeding against the Company and a predecessor, Afexa (Case No. NEW-S-S-140954). The proposed claim asserts that Afexa and the Company made false representations respecting Cold-FX® to residents of British Columbia who purchased the product during the applicable period and that the proposed class has suffered damages as a result. On November 8, 2013, the Plaintiff served an amended notice of civil claim which sought to re-characterize the representation claims and broaden them from what was originally claimed.  On December 8, 2014, the Company filed a motion to strike certain elements of the Plaintiff’s claim for failure to state a cause of action. In response, the Plaintiff proposed further amendments to its claim. The hearing on the motion to strike and the Plaintiff’s amended claim was held on February 4, 2015 and a decision is pending. A date for the certification hearing has been tentatively scheduled for June 22, 2015. The Company denies the allegations being made and is vigorously defending this matter.
	Product Liability Matters
	MoistureLoc™ Product Liability Lawsuits
	Currently, B&L has been served or is aware that it has been named as a defendant in approximately 321 currently active product liability lawsuits (some with multiple plaintiffs) pending in a New York State Consolidated Proceeding described below, as well as in certain other U.S. state courts, on behalf of individuals who claim they suffered personal injury as a result of using a contact lens solution with MoistureLoc™. Two consolidated cases were established to handle MoistureLoc™ claims. First, on August 14, 2006, the Federal Judicial Panel on Multidistrict Litigation created a coordinated proceeding in the Federal District Court for the District of South Carolina. Second, on January 2, 2007, the New York State Litigation Coordinating Panel ordered the consolidation of cases filed in New York State, and assigned the coordination responsibilities to the Supreme Court of the State of New York, New York County. There are approximately 320 currently active non-fusarium cases pending in the New York Consolidated Proceeding. On July 15, 2009, the New York State Supreme Court overseeing the New York Consolidated Proceeding granted B&L’s motion to exclude plaintiffs’ general causation testimony with regard to non-fusarium infections, which effectively excluded plaintiffs from testifying that MoistureLoc™ caused non-fusarium infections. On September 15, 2011, the New York State Appellate Division, First Department, affirmed the Trial Court’s ruling. On February 7, 2012, the New York Court of Appeals denied plaintiffs’ additional appeal. Plaintiffs subsequently filed a motion to renew the trial court’s ruling, and B&L cross-filed a motion for summary judgment to dismiss all remaining claims. On May 31, 2013, the Trial Court denied Plaintiffs’ motion to renew, and granted B&L’s motion for summary judgment, dismissing all remaining non-fusarium claims. On June 28, 2013, Plaintiffs filed a Notice of Appeal to the Trial Court’s ruling. The appeal was argued January 20, 2015. The Court issued its decision on February 10, 2015, denying plaintiffs’ appeal to renew and affirming the lower court’s decision granting B&L’s motion for summary judgment regarding all remaining non-fusarium claims. On March 10, 2015, the plaintiffs filed their motion for leave to appeal this decision and B&L filed its opposition on March 26, 2015. A decision is expected on the motion for leave to appeal by the end of May 2015.
	All matters under jurisdiction of the coordinated proceedings in the Federal District Court for the District of South Carolina have been dismissed, including individual actions for personal injury and a class action purporting to represent a class of consumers who suffered economic claims as a result of purchasing a contact lens solution with MoistureLoc™.
	Currently, B&L has settled approximately 630 cases in connection with MoistureLoc™ product liability suits. All U.S.-based fusarium claims have now been resolved and there are two active fusarium claims involving claimants outside of the United States that remain pending. The parties in these active matters are involved in settlement discussions.
	Salix Legal Proceedings
	The following legal or other proceedings involving Salix had been commenced and were ongoing prior to the Salix Acquisition:
	DOJ Subpoena
	On February 1, 2013, Salix received a subpoena from the U.S. Attorney’s Office for the Southern District of New York requesting documents regarding sales and promotional practices for its Xifaxan®, Relistor® and Apriso® products. Salix and the Company are continuing to respond to the subpoena and intend to cooperate fully with the subpoena and related government investigation.
	Salix SEC Investigation
	The SEC is conducting an investigation into possible securities law violations by Salix relating to disclosures by Salix of inventory amounts in the distribution channel and related issues in press releases, on analyst calls and in Salix’s various SEC filings, as well as related accounting issues. Salix and the Company are cooperating with the SEC in its investigation, including through the provisions of documents to the SEC Enforcement Staff. We cannot predict the outcome or the duration of the SEC investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on Salix or the Company arising out of the SEC investigation.
	Salix Securities Litigation
	Beginning on November 7, 2014, three putative class action lawsuits were filed by shareholders of Salix, each of which generally alleges that Salix and certain of its former officers and directors violated federal securities laws in connection with Salix’s disclosures regarding certain products, including with respect to disclosures concerning historic wholesaler inventory levels, business prospects and demand, reserves and internal controls.  Two of these actions were filed in the U.S. District Court for the Southern District of New York, and are captioned: Woburn Retirement System v. Salix Pharmaceuticals, Ltd., et al. (Case No: 1:14-CV-08925 (KMW)), and Bruyn v. Salix Pharmaceuticals, Ltd., et al. (Case No. 1:14-CV-09226 (KMW)).  These two actions have been consolidated and an initial schedule has been set. Salix and the Company are vigorously defending this consolidated matter. A third action was filed in the U.S. District Court for the Eastern District of North Carolina under the caption Grignon v. Salix Pharmaceuticals, Ltd. et al. (Case No. 5:14-cv-00804-D), but was subsequently voluntarily dismissed.

SEGMENT_INFORMATION

SEGMENT INFORMATION	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION
	Reportable Segments
	The Company has two operating and reportable segments: (i) Developed Markets and (ii) Emerging Markets. The following is a brief description of the Company’s segments:
	•	Developed Markets consists of (i) sales in the U.S. of pharmaceutical products, OTC products, and medical device products, as well as alliance and contract service revenues, in the areas of eye health, dermatology and podiatry, aesthetics, and dentistry, (ii) sales in the U.S. of pharmaceutical products indicated for the treatment of neurological and other diseases, as well as alliance revenue from the licensing of various products we developed or acquired, and (iii) pharmaceutical products, OTC products, and medical device products sold in Canada, Australia, New Zealand, Western Europe and Japan.
	•	Emerging Markets consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products. Products are sold primarily in Central and Eastern Europe (primarily Poland and Russia), Asia, Latin America (Mexico, Brazil, and Argentina and exports out of Mexico to other Latin American markets), Africa and the Middle East.
	Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as restructuring and acquisition-related costs, other (income) expense, and in-process research and development impairments and other charges, are not included in the measure of segment profit, as management excludes these items in assessing financial performance.
	Corporate includes the finance, treasury, tax and legal operations of the Company’s businesses and maintains and/or incurs certain assets, liabilities, expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In addition, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on Company-wide performance rather than the operating performance of any single segment.
	Segment Revenues and Profit
	Segment revenues and profit for the three-month periods ended March 31, 2015 and 2014 were as follows:
		Three Months Ended
		March 31,
		2015			2014
	Revenues:
	Developed Markets(1)	$	1,764.40		$	1,421.80
	Emerging Markets(2)	426.5			464.4
	Total revenues	2,190.90			1,886.20
	Segment profit:
	Developed Markets(3)	636			439.3
	Emerging Markets(4)	54.6			68.1
	Total segment profit	690.6			507.4
	Corporate(5)	(69.2		)	(38.1		)
	Restructuring, integration and other costs	(55.0		)	(133.6		)
	In-process research and development impairments and other charges	—			(12.0		)
	Acquisition-related costs	(9.8		)	(1.5		)
	Acquisition-related contingent consideration	(7.1		)	(8.9		)
	Other (expense) income	(6.1		)	43.3
	Operating income	543.4			356.6
	Interest income	0.9			1.8
	Interest expense	(297.8		)	(246.5		)
	Loss on extinguishment of debt	(20.0		)	(93.7		)
	Foreign exchange and other	(71.1		)	(13.4		)
	Income before provision for income taxes	$	155.4		$	4.8
	____________________________________
	-1	Developed Markets segment revenues reflect incremental product sales revenue in the three-month period ended March 31, 2015 from 2014 and 2015 acquisitions of $208 million, in the aggregate.
	-2	Emerging Markets segment revenues reflect incremental product sales revenue in the three-month period ended March 31, 2015 from 2014 acquisitions of $12 million, in the aggregate.
	-3	Developed Markets segment profit in the three-month period ended March 31, 2015 reflects the impact of acquisition accounting adjustments related to the fair value adjustments to inventory and identifiable intangible assets of $314 million, in the aggregate.
	-4	Emerging Markets segment profit in the three-month period ended March 31, 2015 reflects the impact of acquisition accounting adjustments related to the fair value adjustments to inventory and identifiable intangible assets of $76 million, in the aggregate.
	-5	Corporate reflects non-restructuring-related share-based compensation expense of $24 million and $15 million in the three-month periods ended March 31, 2015 and 2014, respectively.
	Segment Assets
	Total assets by segment as of March 31, 2015 and December 31, 2014 were as follows:
		As of			As of
		March 31,			December 31,
		2015			2014
	Assets:
	Developed Markets(1)	$	30,106.20		$	19,093.40
	Emerging Markets(2)	6,025.10			6,332.90
		36,131.30			25,426.30
	Corporate	2,434.60			926.7
	Total assets	$	38,565.90		$	26,353.00
	____________________________________
	-1	Developed Markets segment assets as of March 31, 2015 reflect the provisional amounts of identifiable intangible assets and goodwill of the 2015 acquisitions of $759 million and $42 million, in the aggregate, respectively.
	-2	Emerging Markets segment assets as of March 31, 2015 reflect the provisional amounts of identifiable intangible assets and goodwill of the 2015 acquisitions of $93 million and $9 million, in the aggregate, respectively.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS
	Salix Merger
	On April 1, 2015, the Company acquired Salix, pursuant to the Merger Agreement, among the Company, Valeant, Sun Merger Sub, Inc., a wholly owned subsidiary of Valeant (“Sun Merger Sub”), and Salix. The total enterprise value of the transaction is approximately $16 billion. Salix is a specialty pharmaceutical company dedicated to developing and commercializing prescription drugs and medical devices used in treatment of variety of gastrointestinal (GI) disorders with a portfolio of over 20 marketed products, including Xifaxan®, Apriso®, Uceris®, and Relistor®.
	In accordance with the terms of the Merger Agreement, Sun Merger Sub commenced a tender offer (the “Offer”) for all of Salix’s outstanding shares of common stock, par value $0.001 per share (the “Salix Shares”), at a purchase price of $173.00 per Salix Share, net to the holder in cash, without interest, less any applicable withholding taxes. The Offer expired on April 1, 2015, as scheduled. A sufficient number of Salix Shares were validly tendered in the Offer such that the minimum tender condition to the Offer was satisfied, and Sun Merger Sub accepted for payment all such tendered Salix Shares. Following the expiration of the Offer on April 1, 2015, Sun Merger Sub merged with and into Salix, with Salix surviving as a wholly owned subsidiary of Valeant (the “Merger”). The Merger was governed by Section 251(h) of the General Corporation Law of the State of Delaware, with no stockholder vote required to consummate the Merger. At the effective time of the Merger, each Salix Share then outstanding was converted into the right to receive $173.00 in cash, without interest, less any applicable withholding taxes, except for Salix Shares then owned by the Company or Salix or their respective wholly-owned subsidiaries, which Salix Shares were cancelled for no consideration.
	In connection with the Merger, each unexpired and unexercised option to purchase Salix Shares (the “Salix Options”), whether or not then exercisable or vested, was cancelled and, in exchange therefor, each former holder of any such cancelled Salix Option was entitled to receive, a payment in cash (subject to any applicable withholding or other taxes required by applicable law to be withheld) of an amount equal to the product of (i) the total number of Salix Shares previously subject to such Salix Option and (ii) the excess, if any, of $173.00 over the exercise price per Salix Share previously subject to such Salix Option. Each unvested Salix Share subject to forfeiture restrictions, repurchase rights or other restrictions (the “Salix Restricted Stock”) automatically became fully vested and was cancelled and, in exchange therefor, each former holder of such cancelled Salix Restricted Stock was entitled to receive, a payment in cash (subject to any applicable withholding or other taxes required by applicable law to be withheld) equal to $173.00 per share of Salix Restricted Stock.
	The Salix Acquisition (including the Offer and the Merger), as well as related transactions and expenses, were funded through a combination of: (i) the proceeds from an issuance of senior unsecured notes that closed on March 27, 2015; (ii) the proceeds from the Incremental Term Loan Facilities (as described below); (iii) the proceeds from a registered offering of Valeant’s common shares in the United States that closed on March 27, 2015; and (iv) cash on hand.
	For further information regarding the debt and equity issuances, see note 8 titled "LONG-TERM DEBT" and note 11 titled "SHAREHOLDERS' EQUITY", respectively.
	The transaction will be accounted for as a business combination under the acquisition method of accounting. The Company will record the assets acquired and liabilities assumed at their fair values as of the acquisition date. Due to the limited time since the closing of the acquisition, the valuation efforts and related acquisition accounting are incomplete at the time of filing of the consolidated financial statements. As a result, the Company is unable to provide amounts recognized as of the acquisition date for major classes of assets and liabilities acquired, including goodwill. In addition, because the acquisition accounting is incomplete, the Company is unable to provide the supplemental pro forma revenue and earnings for the combined entity, as the pro forma adjustments are expected to primarily consist of estimates for the amortization of identifiable intangible assets acquired and related income tax effects, which will result from the purchase price allocation and determination of the fair values for the assets acquired and liabilities assumed.
	Incremental Term Loan Facilities
	Concurrently with the Salix Acquisition (described above), the Company obtained incremental term loan commitments in the aggregate principal amount of $5.15 billion (the "Incremental Term Loan Facilities") under its existing Credit Agreement. The Incremental Term Loan Facilities consist of (1) $1.00 billion of tranche A term loans (the "Series A-4 Tranche A Term Loan Facility"), which have not been drawn as of April 30, 2015, bearing interest at a rate per annum equal to, at the election of the Company, (i) the base rate plus a range between 0.75% and 1.25% or (ii) LIBO rate plus a range between 1.75% and 2.25%, in each case, depending on the Company's leverage ratio and having terms that are consistent with the Company's existing tranche A term loans, and (2) $4.15 billion of tranche B term loans (the "Series F Tranche B Term Loan Facility"), which were fully drawn in April 2015, bearing interest at a rate per annum equal to, at election of the Company, (i) the base rate plus a range between 2.00% and 2.25% or (ii) LIBO rate plus a range between 3.00% and 3.25%, depending on the Company's secured leverage ratio and subject to a 1.75% base rate floor and 0.75% LIBO rate floor, and having terms that are consistent with the Company's existing tranche B term loans. The Incremental Term Loan Facilities have an original issue discount of approximately $21 million.
	The Series A-4 Tranche A Term Loan Facility matures on April 1, 2020 and amortizes quarterly commencing June 30, 2015 at the initial annual rate of 5%. The amortization schedule under the Series A-4 Tranche A Term Loan Facility will increase to 10% annually commencing June 30, 2016 and 20% annually commencing June 30, 2017, payable in quarterly installments. The Series F Tranche B Term Loan Facility matures on April 1, 2022 and amortizes quarterly commencing June 30, 2015 at an annual rate of 1%.

SIGNIFICANT_ACCOUNTING_POLICIE1

SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
	The accompanying unaudited consolidated financial statements (the “unaudited consolidated financial statements”) have been prepared by the Company in United States (“U.S.”) dollars and in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting, which do not conform in all respects to the requirements of U.S. GAAP for annual financial statements. Accordingly, these condensed notes to the unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto prepared in accordance with U.S. GAAP that are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 (the “2014 Form 10-K”). The unaudited consolidated financial statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company’s audited consolidated financial statements for the year ended December 31, 2014. The unaudited consolidated financial statements reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations for the interim periods presented.
Reclassifications	Reclassifications
	Certain reclassifications have been made to prior year amounts to conform with the current year presentation.
Use of Estimates	Use of Estimates
	In preparing the unaudited consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the unaudited consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the operating results for the interim periods presented are not necessarily indicative of the results expected for the full year.
	On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s results of operations and financial position could be materially impacted.
Recently Issued Accounting Standards, Not Adopted as of March 31, 2015	Recently Issued Accounting Standards, Not Adopted as of March 31, 2015
	In May 2014, the Financial Accounting Standard Board ("FASB") and the International Accounting Standards Board issued converged guidance on recognizing revenue from contracts with customers. The core principle of the revenue model is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In applying the revenue model to contracts within its scope, an entity will: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. In addition to these provisions, the new standard provides implementation guidance on several other topics, including the accounting for certain revenue-related costs, as well as enhanced disclosure requirements. The new guidance requires entities to disclose both quantitative and qualitative information that enables users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The guidance is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016. Early application is not permitted. Entities have the option of using either a full retrospective or a modified approach to adopt the guidance. The Company is evaluating the impact of adoption of this guidance on its financial position and results of operations.
	In August 2014, the FASB issued guidance which requires management to assess an entity’s ability to continue as a going concern and to provide related disclosures in certain circumstances. Under the new guidance, disclosures are required when conditions give rise to substantial doubt about an entity’s ability to continue as a going concern within one year from the financial statement issuance date. The guidance is effective for annual periods ending after December 15, 2016, and all annual and interim periods thereafter. Early application is permitted. The adoption of this guidance will not have any impact on the Company’s financial position and results of operations and, at this time, the Company does not expect any impact on its disclosures.
	In February 2015, the FASB issued guidance which amends certain consolidation requirements. The new guidance has the following stipulations, among others: (i) eliminates the presumption that a general partner should consolidate a limited partnership and eliminates the consolidation model specific to limited partnerships, (ii) clarifies when fees paid to a decision maker should be a factor to include in the consolidation of variable interest entities (“VIEs”), (iii) amends the guidance for assessing how relationships of related parties affect the consolidation analysis of VIEs, and (iv) reduces the number of VIE consolidation models from two to one by eliminating the indefinite deferral for certain investment funds. The guidance is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2015. Early application is permitted. Entities have the option of using either a full retrospective or a modified retrospective approach to adopt the guidance. The Company is evaluating the impact of adoption of this guidance on its financial position and results of operations.
	In April 2015, the FASB issued guidance which requires debt issuance costs to be presented in the balance sheet as a direct deduction from the carrying value of the associated debt, consistent with the presentation of a debt discount. The guidance is effective for annual periods beginning after December 15, 2015, and all annual and interim periods thereafter. Early application is permitted. The adoption of this guidance, which will be applied retrospectively, will not have a material impact on the Company’s financial position and results of operations, as it will impact balance sheet presentation only.

BUSINESS_COMBINATIONS_Tables

BUSINESS COMBINATIONS (Tables)	3 Months Ended
	Mar. 31, 2015
Business Acquisition [Line Items]
Schedule of pro forma impact of merger and acquisition	The following table presents unaudited pro forma consolidated results of operations for the three-month periods ended March 31, 2015 and 2014, as if the 2015 acquisitions had occurred as of January 1, 2014 and the 2014 acquisitions had occurred as of January 1, 2013.
		Three Months Ended
		March 31,
		2015				2014
	Revenues	$	2,270.40			$	2,056.40
	Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.	93.8				(73.9		)
	Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:
	Basic	$	0.28			$	(0.22	)
	Diluted	$	0.27			$	(0.22	)
2015 Acquisitions
Business Acquisition [Line Items]
Schedule of estimated fair value of assets acquired and liabilities assumed
			Amounts
			Recognized as of
			Acquisition Dates
	Cash		$	80.2
	Accounts receivable(a)		23.9
	Inventories		104.3
	Other current assets		17.9
	Property, plant and equipment		71.3
	Identifiable intangible assets, excluding acquired IPR&D(b)		851.8
	Acquired IPR&D		1.5
	Other non-current assets		1.2
	Deferred tax asset, net		5.8
	Current liabilities(c)		(91.8		)
	Non-current liabilities(c)		(96.0		)
	Total identifiable net assets		970.1
	Goodwill(d)		50.8
	Total fair value of consideration transferred		$	1,020.90
	________________________
	(a)	The gross contractual amount of trade accounts receivable acquired was $24 million, which the Company expects will be fully collectible.
	(b)	The following table summarizes the provisional amounts and useful lives assigned to identifiable intangible assets:
			Weighted-		Amounts
			Average		Recognized as of
			Useful Lives		Acquisition Dates
			(Years)
	Product brands		7		$	580.4
	Product rights		3		42.6
	Partner relationships		8		7.8
	Technology/know-how		10		219
	Other		6		2
	Total identifiable intangible assets acquired		8		$	851.8
	(c)	As part of the Marathon acquisition, the Company assumed a contingent consideration liability related to potential payments for Isuprel® and Nitropress®, the amounts of which are dependent on the timing of generic entrants for these products. The fair value of the liability was determined using probability-weighted projected cash flows, with $41 million classified in Current liabilities and $46 million classified in Non-current liabilities in the table above.
	(d)	The goodwill relates primarily to the Marathon and other smaller acquisitions. Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Substantially all of the goodwill is expected to be deductible for tax purposes. The goodwill represents primarily the cost savings, operating synergies and other benefits expected to result from combining the operations with those of the Company.
	The provisional amount of goodwill has been allocated primarily to the Company’s Developed Markets segment.
Summary of amounts and useful lives assigned to identifiable intangible assets	The following table summarizes the provisional amounts and useful lives assigned to identifiable intangible assets:
			Weighted-		Amounts
			Average		Recognized as of
			Useful Lives		Acquisition Dates
			(Years)
	Product brands		7		$	580.4
	Product rights		3		42.6
	Partner relationships		8		7.8
	Technology/know-how		10		219
	Other		6		2
	Total identifiable intangible assets acquired		8		$	851.8
2014 Acquisitions
Business Acquisition [Line Items]
Schedule of estimated fair value of assets acquired and liabilities assumed
			Amounts				Measurement				Amounts
			Recognized as of				Period				Recognized as of
			Acquisition Dates				Adjustments(a)				31-Mar-15
											(as adjusted)
	Cash and cash equivalents		$	33.6			$	1			$	34.6
	Accounts receivable(b)		87.7				(6.5		)		81.2
	Assets held for sale(c)		125.7				(0.6		)		125.1
	Inventories		170.4				(15.3		)		155.1
	Other current assets		19.1				(1.1		)		18
	Property, plant and equipment, net		58.5				(3.0		)		55.5
	Identifiable intangible assets, excluding acquired IPR&D(d)		697.2				6.3				703.5
	Acquired IPR&D(e)		65.8				(2.8		)		63
	Other non-current assets		4				(2.1		)		1.9
	Current liabilities		(152.0		)		(18.2		)		(170.2		)
	Long-term debt, including current portion		(11.2		)		—				(11.2		)
	Deferred income taxes, net		(116.0		)		36				(80.0		)
	Other non-current liabilities		(13.4		)		(0.1		)		(13.5		)
	Total identifiable net assets		969.4				(6.4		)		963
	Noncontrolling interest		(15.0		)		0.2				(14.8		)
	Goodwill(f)		410.4				(9.5		)		400.9
	Total fair value of consideration transferred		$	1,364.80			$	(15.7	)		$	1,349.10
	________________________
	(a)	The measurement period adjustments primarily reflect: (i) a decrease in the net deferred tax liability primarily related to the PreCision and Solta Medical acquisitions and (ii) reductions in the estimated fair value of inventory for Solta Medical and other smaller acquisitions. The measurement period adjustments were made to reflect facts and circumstances existing as of the acquisition date, and did not result from intervening events subsequent to the acquisition date. These adjustments did not have a significant impact on the Company’s previously reported consolidated financial statements and, therefore, the Company has not retrospectively adjusted those financial statements.
	(b)	The fair value of trade accounts receivable acquired was $81 million, with the gross contractual amount being $88 million, of which the Company expects that $7 million will be uncollectible.
	(c)	Assets held for sale relate to the Tretin-X® product rights and the product rights for the generic tretinoin gel and cream products acquired in the PreCision acquisition, which were subsequently divested in the third quarter of 2014.
	(d)	The following table summarizes the provisional amounts and useful lives assigned to identifiable intangible assets:
			Weighted-		Amounts				Measurement				Amounts
			Average		Recognized as of				Period				Recognized as of
			Useful Lives		Acquisition Dates				Adjustments				31-Mar-15
			(Years)										(as adjusted)
	Product brands		10		$	506			$	8.3			$	514.3
	Product rights		8		95.2				(3.3		)		91.9
	Corporate brand		15		28.9				1.7				30.6
	In-licensed products		9		1.5				(0.4		)		1.1
	Partner relationships		9		37.5				—				37.5
	Other		9		28.1				—				28.1
	Total identifiable intangible assets acquired		10		$	697.2			$	6.3			$	703.5
	(e)	The acquired IPR&D assets primarily relate to programs from smaller acquisitions. In addition, the Solta Medical acquisition includes a program for the development of a next generation Thermage® product.
	(f)	The goodwill relates primarily to the PreCision and Solta Medical acquisitions. Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Substantially all of the goodwill is not expected to be deductible for tax purposes. The goodwill recorded from the PreCision and Solta Medical acquisitions represents the following:
	•	cost savings, operating synergies and other benefits expected to result from combining the operations of PreCision and Solta Medical with those of the Company;
	•	the Company’s expectation to develop and market new products and technology; and
	•	intangible assets that do not qualify for separate recognition (for instance, PreCision’s and Solta Medical’s assembled workforces).
	The provisional amount of goodwill from the PreCision acquisition has been allocated to the Company’s Developed Markets segment ($178 million). The amount of goodwill from the Solta Medical acquisition has been allocated to both the Company’s Developed Markets segment ($56 million) and Emerging Markets segment ($38 million).
Summary of amounts and useful lives assigned to identifiable intangible assets	The following table summarizes the provisional amounts and useful lives assigned to identifiable intangible assets:
			Weighted-		Amounts				Measurement				Amounts
			Average		Recognized as of				Period				Recognized as of
			Useful Lives		Acquisition Dates				Adjustments				31-Mar-15
			(Years)										(as adjusted)
	Product brands		10		$	506			$	8.3			$	514.3
	Product rights		8		95.2				(3.3		)		91.9
	Corporate brand		15		28.9				1.7				30.6
	In-licensed products		9		1.5				(0.4		)		1.1
	Partner relationships		9		37.5				—				37.5
	Other		9		28.1				—				28.1
	Total identifiable intangible assets acquired		10		$	697.2			$	6.3			$	703.5

RESTRUCTURING_INTEGRATION_AND_1

RESTRUCTURING, INTEGRATION AND OTHER COSTS (Tables) (B&L)	3 Months Ended
	Mar. 31, 2015
B&L
Restructuring costs
Schedule of major components of restructuring costs incurred in connection with acquisition-related initiatives	The following table summarizes the major components of the restructuring costs incurred in connection with the B&L Acquisition since the acquisition date through March 31, 2015:
			Employee Termination Costs						IPR&D		Contract
									Termination		Termination,
									Costs		Facility Closure
			Severance and			Share-Based					and Other Costs			Total
			Related Benefits			Compensation(1)
	Balance, January 1, 2013		$	—		$	—		$	—	$	—		$	—
	Costs incurred and/or charged to expense		155.7			52.8			—		25.6			234.1
	Cash payments		(77.8		)	(52.8		)	—		(7.8		)	(138.4		)
	Non-cash adjustments		11.4			—			—		(6.8		)	4.6
	Balance, December 31, 2013		$	89.3		$	—		$	—	$	11		$	100.3
	Costs incurred and charged to expense		46			—			—		23.7			69.7
	Cash payments		(110.7		)	—			—		(24.9		)	(135.6		)
	Non-cash adjustments		(5.7		)	—			—		(5.4		)	(11.1		)
	Balance, December 31, 2014(2)		$	18.9		$	—		$	—	$	4.4		$	23.3
	Costs incurred and charged to expense		3			—			—		0.9			3.9
	Cash payments		(12.6		)	—			—		(1.3		)	(13.9		)
	Non-cash adjustments		(1.5		)	—			—		(1.2		)	(2.7		)
	Balance, March 31, 2015		$	7.8		$	—		$	—	$	2.8		$	10.6
	___________________________________
	-1	Relates to B&L’s previously cancelled performance-based options and the acceleration of unvested stock options for B&L employees as a result of the B&L Acquisition were recognized in Other (income) expense.
	-2	In the three-month period ended March 31, 2014, the Company recognized $29 million of restructuring charges and made payments of $54 million related to the B&L Acquisition.

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Schedule of components and classification of financial assets and liabilities measured at fair value	The following fair value hierarchy table presents the components and classification of the Company’s financial assets and liabilities measured at fair value as of March 31, 2015 and December 31, 2014:
			As of March 31, 2015															As of December 31, 2014
			Carrying				Quoted			Significant				Significant				Carrying				Quoted			Significant		Significant
			Value				Prices			Other				Unobservable				Value				Prices			Other		Unobservable
							in Active			Observable				Inputs								in Active			Observable		Inputs
							Markets for			Inputs				(Level 3)								Markets for			Inputs		(Level 3)
							Identical			(Level 2)												Identical			(Level 2)
							Assets															Assets
							(Level 1)															(Level 1)
	Assets:
	Cash equivalents(1)		$	120.3			$	115		$	5.3			$	—			$	4.6			$	2.8		$	1.8	$	—
	Restricted cash and cash equivalents(2)		$	10,354.90			$	10,354.90		$	—			$	—			$	9.1			$	9.1		$	—	$	—
	Liabilities:
	Derivative financial instruments:
	Foreign exchange contracts(3)		$	(26.6	)		$	—		$	(26.6	)		$	—			$	—			$	—		$	—	$	—
	Acquisition-related contingent consideration		$	(385.2	)		$	—		$	—			$	(385.2	)		$	(308.8	)		$	—		$	—	$	(308.8	)
	___________________________________
	-1	Cash equivalents include highly liquid investments with an original maturity of three months or less at acquisition, primarily including money market funds, reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.
	-2	The restricted cash and cash equivalents is primarily invested in highly liquid money market funds, reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature. Refer to Note 8 titled "LONG-TERM DEBT" for additional information regarding the restricted cash and cash equivalents.
	-3	In March 2015, the Company entered into foreign currency forward-exchange contracts to sell €1.53 billion and buy U.S. Dollars in order to reduce its exposure to the variability in expected cash inflows attributable to the changes in foreign exchange rates related to the €1.50 billion aggregate principal amount and related interest of 4.50% senior unsecured notes due 2023 (the "Euro Notes") issued on March 27, 2015, the proceeds of which were used to finance the Salix Acquisition (see note 8 titled "LONG-TERM DEBT" for additional information). These derivative contracts are not designated as hedges for accounting purposes, and such contracts matured on April 1, 2015 (which coincides with the consummation of the Salix Acquisition). As of March 31, 2015, the Company recorded $27 million within Accrued and other current liabilities in the consolidated balance sheets representing the fair value of these derivatives (the fair value approximates the settlement amount), and a foreign exchange loss of $27 million was recognized in Foreign exchange and other in the consolidated income (loss) for the three-month period ended March 31, 2015.
Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3)	The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3) for the three-month period ended March 31, 2015:
		Balance,				Issuances(a)			Payments(b)				Net				Foreign				Release from Restricted Cash			Balance,
		January 1,											Unrealized				Exchange(d)							March 31,
		2015											Loss(c)											2015(e)
	Acquisition-related contingent consideration	$	(308.8	)		$	(90.2	)	$	14.5			$	(7.1	)		$	3.9			$	2.5		$	(385.2	)
	____________________________________
	(a)	Primarily relates to a contingent consideration liability assumed in the Marathon acquisition, as described in note 3 titled "BUSINESS COMBINATIONS".
	(b)	Primarily relates to payments of acquisition-related contingent consideration for the Elidel®/Xerese®/Zovirax® agreement entered into with Meda Pharma SARL in June 2011 (the "Elidel®/Xerese®/Zovirax® agreement").
	(c)	For the three months ended March 31, 2015, a net loss of $7 million was recognized as Acquisition-related contingent consideration in the consolidated statements of income (loss), primarily reflecting accretion for the time value of money for the Elidel®/Xerese®/Zovirax® agreement.
	(d)	Included in other comprehensive income (loss).
	(e)	For the three months ended March 31, 2015, there were no transfers into or out of Level 3.

INVENTORIES_Tables

INVENTORIES (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Schedule of the components of inventories	The components of inventories as of March 31, 2015 and December 31, 2014 were as follows:
			As of		As of
			March 31,		December 31,
			2015		2014
	Raw materials(1)		$	239.1	$	191.1
	Work in process(1)		101.1		94.2
	Finished goods(1)		658.7		665.3
			998.9		950.6
	___________________________________
	-1	The components of inventories shown in the table above are presented net of allowance for obsolescence.

INTANGIBLE_ASSETS_AND_GOODWILL1

INTANGIBLE ASSETS AND GOODWILL (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of components of intangible assets	The major components of intangible assets as of March 31, 2015 and December 31, 2014 were as follows:
			As of March 31, 2015									As of December 31, 2014
			Gross			Accumulated			Net			Gross		Accumulated			Net
			Carrying			Amortization,			Carrying			Carrying		Amortization,			Carrying
			Amount			Including			Amount			Amount		Including			Amount
						Impairments								Impairments
	Finite-lived intangible assets:
	Product brands		$	10,691.40		$	(3,763.8	)	$	6,927.60		$	10,320.20	$	(3,579.8	)	$	6,740.40
	Corporate brands		352.7			(67.4		)	285.3			364.2		(65.2		)	299
	Product rights		3,248.20			(1,360.8		)	1,887.40			3,225.90		(1,263.8		)	1,962.10
	Partner relationships		203			(102.5		)	100.5			223.1		(107.5		)	115.6
	Technology and other		496.3			(131.6		)	364.7			275.5		(124.3		)	151.2
	Total finite-lived intangible assets		14,991.60			(5,426.1		)	9,565.50			14,408.90		(5,140.6		)	9,268.30
	Indefinite-lived intangible assets:
	Acquired IPR&D		291.6			—			291.6			290.1		—			290.1
	Corporate brand(1)		1,697.50			—			1,697.50			1,697.50		—			1,697.50
			$	16,980.70		$	(5,426.1	)	$	11,554.60		$	16,396.50	$	(5,140.6	)	$	11,255.90
	____________________________________
	-1	Represents the B&L corporate trademark, which has an indefinite useful life and is therefore not amortized.
Schedule of estimated aggregate amortization expense for each of the five succeeding years	Estimated aggregate amortization expense, as of March 31, 2015, for each of the five succeeding years ending December 31 is as follows:
			2015			2016			2017			2018		2019
	Amortization expense(1)		$	1,466.40		$	1,379.50		$	1,317.20		$	1,184.10	$	1,043.60
	____________________________________
	-1	Estimated amortization expense shown in the table above does not include potential future impairments of finite-lived intangible assets, if any, nor does it include any amortization with respect to the Salix Acquisition which was completed on April 1, 2015.
Schedule of changes in the carrying amount of goodwill	The changes in the carrying amount of goodwill in the three-month period ended March 31, 2015 were as follows:
			Developed			Emerging			Total
			Markets			Markets
	Balance, January 1, 2015		$	7,115.00		$	2,231.40		$	9,346.40
	Additions(a)		41.4			9.4			50.8
	Adjustments(b)		4			0.6			4.6
	Foreign exchange and other		(161.2		)	(79.2		)	(240.4		)
	Balance, March 31, 2015		$	6,999.20		$	2,162.20		$	9,161.40
	____________________________________
	(a)	Primarily relates to the Marathon acquisition, as well as other smaller acquisitions (as described in note 3).
	(b)	Primarily reflects the impact of measurement period adjustments related to the PreCision acquisition.

LONGTERM_DEBT_Tables

LONG-TERM DEBT (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Schedule of long-term debt	A summary of the Company’s consolidated long-term debt as of March 31, 2015 and December 31, 2014, respectively, is outlined in the table below:
			Maturity	As of			As of
			Date	March 31,			December 31,
				2015			2014
	Revolving Credit Facility(1)		April 2018	$	225		$	165
	Series A-1 Tranche A Term Loan Facility(1)		April 2016	139.1			139.6
	Series A-2 Tranche A Term Loan Facility(1)		Apr-16	135.3			135.7
	Series A-3 Tranche A Term Loan Facility(1)		Oct-18	1,877.30			1,637.90
	Series D-2 Tranche B Term Loan Facility(1)		Feb-19	1,084.10			1,089.70
	Series C-2 Tranche B Term Loan Facility(1)		Dec-19	834			838.3
	Series E-1 Tranche B Term Loan Facility(1)		Aug-20	2,529.50			2,544.90
	Senior Notes:
	6.88%		December 2018	—			497.7
	7.00%		October 2020	687.6			687.5
	6.75%		August 2021	650			650
	7.25%		July 2022	543.4			543.2
	6.38%		Oct-20	2,226.60			2,225.60
	6.75%		Aug-18	1,586.80			1,585.80
	7.50%		Jul-21	1,609.10			1,608.40
	5.63%		Dec-21	892.9			892.6
	5.50%		Mar-23	991.7			—
	5.38%		Mar-20	1,977.60			—
	5.88%		May-23	3,213.50			—
	4.50%(2)		May-23	1,591.50			—
	6.13%		Apr-25	3,213.50			—
	Other(3)		Various	12.2			12.7
				26,020.70			15,254.60
	Less current portion			(122.8		)	(0.9		)
	Total long-term debt			$	25,897.90		$	15,253.70
	____________________________________
	-1	Together, the “Senior Secured Credit Facilities” under the Company’s Third Amended and Restated Credit and Guaranty Agreement, as amended (the “Credit Agreement”).
	-2	Represents the U.S. dollar equivalent of Euro-denominated debt (discussed below).
	-3	Relates primarily to the debentures from B&L.

SHAREBASED_COMPENSATION_Tables

SHARE-BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of the components and classification of share-based compensation expense	The following table summarizes the components and classification of share-based compensation expense related to stock options and restricted share units (“RSUs”) for the three-month periods ended March 31, 2015 and 2014:
		Three Months Ended
		March 31,
		2015		2014
	Stock options	$	3.9	$	5.1
	RSUs	31.1		19.7
	Share-based compensation expense	$	35	$	24.8
	Research and development expenses	$	1.5	$	1.4
	Selling, general and administrative expenses	33.5		23.4
	Share-based compensation expense	$	35	$	24.8

PENSION_AND_POSTRETIREMENT_EMP1

PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)	3 Months Ended
	Mar. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Components of net periodic benefit cost	The following table provides the components of net periodic (benefit) cost for the Company’s defined benefit pension plans and postretirement benefit plan for the three-month periods ended March 31, 2015 and 2014:
		Pension Benefit Plans												Postretirement
														Benefit
		U.S. Plan						Non-U.S. Plans						Plan
		Three Months Ended March 31,
		2015			2014			2015			2014			2015			2014
	Service cost	$	0.4		$	0.1		$	0.8		$	1		$	0.5		$	0.4
	Interest cost	2.4			2.7			1.6			2.2			0.5			0.6
	Expected return on plan assets	(3.6		)	(3.7		)	(2.0		)	(2.0		)	(0.1		)	(0.1		)
	Amortization of prior service credit	—			—			(0.1		)	—			(0.6		)	(0.6		)
	Amortization of net loss	—			—			0.4			—			—			—
	Net periodic (benefit) cost	$	(0.8	)	$	(0.9	)	$	0.7		$	1.2		$	0.3		$	0.3

SHAREHOLDERS_EQUITY_Tables

SHAREHOLDERS' EQUITY (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Schedule of Shareholders' equity
		Valeant Pharmaceuticals International, Inc. Shareholders
		Common Shares			Additional			Accumulated			Accumulated			Valeant			Noncontrolling			Total
					Paid-In			Deficit			Other			Pharmaceuticals			Interest			Equity
					Capital						Comprehensive			International, Inc.
											Loss			Shareholders’
		Shares	Amount											Equity
	Balance, January 1, 2014	333	$	8,301.20	$	228.8		$	(3,278.5	)	$	(132.8	)	$	5,118.70		$	114.6		$	5,233.30
	Common shares issued under share-based compensation plans	0.5	15		(11.5		)	—			—			3.5			—			3.5
	Share-based compensation	—	—		24.8			—			—			24.8			—			24.8
	Employee withholding taxes related to share-based awards	—	—		(27.7		)	—			—			(27.7		)	—			(27.7		)
	Tax benefits from stock options exercised	—	—		1.2			—			—			1.2			—			1.2
	Acquisition of noncontrolling interest	—	—		(1.1		)	—			—			(1.1		)	(2.2		)	(3.3		)
		333.5	8,316.20		214.5			(3,278.5		)	(132.8		)	5,119.40			112.4			5,231.80
	Comprehensive loss:
	Net loss (income)	—	—		—			(22.6		)	—			(22.6		)	2.3			(20.3		)
	Other comprehensive loss	—	—		—			—			(7.2		)	(7.2		)	(0.8		)	(8.0		)
	Total comprehensive loss													(29.8		)	1.5			(28.3		)
	Balance, March 31, 2014	333.5	$	8,316.20	$	214.5		$	(3,301.1	)	$	(140.0	)	$	5,089.60		$	113.9		$	5,203.50
	Balance, January 1, 2015	334.4	$	8,349.20	$	243.9		$	(2,365.0	)	$	(915.9	)	$	5,312.20		$	122.3		$	5,434.50
	Issuance of common stock (see below)	7.3	1,431.90		—			—			—			1,431.90			—			1,431.90
	Common shares issued under share-based compensation plans	0.6	29.2		(14.7		)	—			—			14.5			—			14.5
	Share-based compensation	—	—		35			—			—			35			—			35
	Employee withholding taxes related to share-based awards	—	—		(21.2		)	—			—			(21.2		)	—			(21.2		)
	Tax benefits from stock options exercised	—	—		17.9			—			—			17.9			—			17.9
		342.3	9,810.30		260.9			(2,365.0		)	(915.9		)	6,790.30			122.3			6,912.60
	Comprehensive loss:
	Net income (loss)	—	—		—			73.7			—			73.7			0.8			74.5
	Other comprehensive loss	—	—		—			—			(411.7		)	(411.7		)	(0.2		)	(411.9		)
	Total comprehensive loss													(338.0		)	0.6			(337.4		)
	Balance, March 31, 2015	342.3	$	9,810.30	$	260.9		$	(2,291.3	)	$	(1,327.6	)	$	6,452.30		$	122.9		$	6,575.20
	____________________________________
	On March 27, 2015, the Company completed, pursuant to an Underwriting Agreement dated March 17, 2015 with Deutsche Bank Securities Inc. on behalf of several underwriters, a registered offering in the United States of 7,286,432 of its common shares, no par value, at a price of $199.00 per common share, for aggregate gross proceeds of approximately $1.45 billion. In connection with the issuance of these new common shares, the Company incurred approximately $18 million of issuance costs, which has been reflected as reduction to the gross proceeds from the equity issuance. The proceeds of this offering were used to fund the Salix Acquisition. The Company granted the underwriters an option to purchase additional common shares equal to up to 15% of the common shares initially issued in the offering. This option was not exercised by the underwriters.

ACCUMULATED_OTHER_COMPREHENSIV1

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)	3 Months Ended
	Mar. 31, 2015
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Schedule of the components of accumulated other comprehensive loss	The components of accumulated other comprehensive loss as of March 31, 2015 and 2014, were as follows:
			Foreign			Pension			Total
			Currency			Adjustment
			Translation
			Adjustment
	Balance, January 1, 2014		$	(170.3	)	$	37.5		$	(132.8	)
	Foreign currency translation adjustment		(6.6		)	—			(6.6		)
	Pension adjustment(1)		—			(0.6		)	(0.6		)
	Balance, March 31, 2014		$	(176.9	)	$	36.9		$	(140.0	)
	Balance, January 1, 2015		$	(886.5	)	$	(29.4	)	$	(915.9	)
	Foreign currency translation adjustment		(411.3		)	—			(411.3		)
	Pension adjustment(1)		—			(0.4		)	(0.4		)
	Balance, March 31, 2015		$	(1,297.8	)	$	(29.8	)	$	(1,327.6	)
	____________________________________
	-1	Reflects changes in defined benefit obligations and related plan assets of the Company’s defined benefit pension plans and the U.S. postretirement benefit plan (refer to note 10 titled "PENSION AN POSTRETIREMENT EMPLOYEE BENEFIT PLANS").

EARNINGS_LOSS_PER_SHARE_Tables

EARNINGS (LOSS) PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Schedule of calculation of earnings per share	Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc. for the three-month periods ended March 31, 2015 and 2014 were calculated as follows:
		Three Months Ended
		March 31,
		2015		2014
	Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.	$	73.7	$	(22.6	)
	Basic weighted-average number of common shares outstanding	336.8		334.9
	Diluted effect of stock options, RSUs and other(a)	6.6		—
	Diluted weighted-average number of common shares outstanding	343.4		334.9
	Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:
	Basic	$	0.22	$	(0.07	)
	Diluted	$	0.21	$	(0.07	)
	____________________________________
	(a)	In the three-month period ended March 31, 2014, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been as follows:
			Three Months Ended
			March 31,
			2014
	Basic weighted-average number of common shares outstanding		334.9
	Dilutive effect of stock options and RSUs		6.6
	Diluted weighted-average number of common shares outstanding		341.5
Schedule of dilutive effect of stock options, RSUs and Convertible Notes on weighted-average number of common shares outstanding	The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been as follows:
			Three Months Ended
			March 31,
			2014
	Basic weighted-average number of common shares outstanding		334.9
	Dilutive effect of stock options and RSUs		6.6
	Diluted weighted-average number of common shares outstanding		341.5

SEGMENT_INFORMATION_Tables

SEGMENT INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Schedule of segment revenues and profit	Segment revenues and profit for the three-month periods ended March 31, 2015 and 2014 were as follows:
		Three Months Ended
		March 31,
		2015			2014
	Revenues:
	Developed Markets(1)	$	1,764.40		$	1,421.80
	Emerging Markets(2)	426.5			464.4
	Total revenues	2,190.90			1,886.20
	Segment profit:
	Developed Markets(3)	636			439.3
	Emerging Markets(4)	54.6			68.1
	Total segment profit	690.6			507.4
	Corporate(5)	(69.2		)	(38.1		)
	Restructuring, integration and other costs	(55.0		)	(133.6		)
	In-process research and development impairments and other charges	—			(12.0		)
	Acquisition-related costs	(9.8		)	(1.5		)
	Acquisition-related contingent consideration	(7.1		)	(8.9		)
	Other (expense) income	(6.1		)	43.3
	Operating income	543.4			356.6
	Interest income	0.9			1.8
	Interest expense	(297.8		)	(246.5		)
	Loss on extinguishment of debt	(20.0		)	(93.7		)
	Foreign exchange and other	(71.1		)	(13.4		)
	Income before provision for income taxes	$	155.4		$	4.8
	____________________________________
	-1	Developed Markets segment revenues reflect incremental product sales revenue in the three-month period ended March 31, 2015 from 2014 and 2015 acquisitions of $208 million, in the aggregate.
	-2	Emerging Markets segment revenues reflect incremental product sales revenue in the three-month period ended March 31, 2015 from 2014 acquisitions of $12 million, in the aggregate.
	-3	Developed Markets segment profit in the three-month period ended March 31, 2015 reflects the impact of acquisition accounting adjustments related to the fair value adjustments to inventory and identifiable intangible assets of $314 million, in the aggregate.
	-4	Emerging Markets segment profit in the three-month period ended March 31, 2015 reflects the impact of acquisition accounting adjustments related to the fair value adjustments to inventory and identifiable intangible assets of $76 million, in the aggregate.
	-5	Corporate reflects non-restructuring-related share-based compensation expense of $24 million and $15 million in the three-month periods ended March 31, 2015 and 2014, respectively.
Schedule of total assets by segment	Total assets by segment as of March 31, 2015 and December 31, 2014 were as follows:
		As of			As of
		March 31,			December 31,
		2015			2014
	Assets:
	Developed Markets(1)	$	30,106.20		$	19,093.40
	Emerging Markets(2)	6,025.10			6,332.90
		36,131.30			25,426.30
	Corporate	2,434.60			926.7
	Total assets	$	38,565.90		$	26,353.00
	____________________________________
	-1	Developed Markets segment assets as of March 31, 2015 reflect the provisional amounts of identifiable intangible assets and goodwill of the 2015 acquisitions of $759 million and $42 million, in the aggregate, respectively.
	-2	Emerging Markets segment assets as of March 31, 2015 reflect the provisional amounts of identifiable intangible assets and goodwill of the 2015 acquisitions of $93 million and $9 million, in the aggregate, respectively.

DESCRIPTION_OF_BUSINESS_Detail

DESCRIPTION OF BUSINESS (Details)	Mar. 31, 2015
	country
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of Countries in which Entity Operates (over 100 countries)	100

BUSINESS_COMBINATIONS_Narrativ

BUSINESS COMBINATIONS - Narrative (Details) (USD $)	3 Months Ended		0 Months Ended	12 Months Ended	3 Months Ended	0 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Feb. 23, 2015	Dec. 31, 2014	Sep. 30, 2014	Jan. 23, 2014	Feb. 10, 2015	Jul. 07, 2014
Business Acquisition [Line Items]
Purchase price net of cash received	$795	$306.30
Acquisition of businesses, contingent and deferred consideration obligations at fair value	286.9	21.7
Acquisition-related costs	9.8	1.5
Acquisition-related contingent consideration	186.3			141.8
Pro forma acquisition accounting adjustment on inventory sold subsequent to acquisition date	24	5
2015 Acquisitions
Business Acquisition [Line Items]
Aggregate purchase price	1,020
Acquisition of businesses, contingent and deferred consideration obligations at fair value	90
Current liabilities	91.8
Non-current liabilities	96
Acquisition-related costs	8
Revenues of acquiree since acquisition date	168
Net earnings (loss), net of tax of acquiree since acquisition date	43
Dendreon
Business Acquisition [Line Items]
Purchase price net of cash received			415
Gross purchase price			495
Cash received from Acquisition			80
Stock consideration transferred			50
Marathon
Business Acquisition [Line Items]
Aggregate purchase price							286
Assumed liability owed to a third party							64
Current liabilities							41
Non-current liabilities							46
2014 Acquisitions
Business Acquisition [Line Items]
Aggregate purchase price				1,350
Acquisition of businesses, contingent and deferred consideration obligations at fair value				94
Current liabilities	170.2
PreCision Dermatology, Inc.
Business Acquisition [Line Items]
Aggregate purchase price								453
Acquisition-related contingent consideration								25
PreCision Dermatology, Inc. | Other (Income) Expense
Business Acquisition [Line Items]
Post-combination expense					20
Solta Medical, Inc.
Business Acquisition [Line Items]
Aggregate purchase price						293
Per share consideration (in usd per share)						$2.92
Repayments of long-term debt						$44

BUSINESS_COMBINATIONS_Estimate

BUSINESS COMBINATIONS - Estimated fair values of the assets acquired and liabilities assumed (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Jul. 07, 2014
In Millions, unless otherwise specified
Assets acquired and liabilities assumed
Goodwill	$9,161.40	$9,346.40
2015 Acquisitions
Assets acquired and liabilities assumed
Cash and cash equivalents	80.2
Accounts receivable	23.9
Inventories	104.3
Other current assets	17.9
Property, plant and equipment, net	71.3
Identifiable intangible assets, excluding acquired IPR&D	851.8
Acquired IPR&D	1.5
Other non-current assets	1.2
Deferred tax asset, net	5.8
Current liabilities	-91.8
Non-current liabilities	-96
Total identifiable net assets	970.1
Goodwill	50.8
Total fair value of consideration transferred	1,020.90
2014 Acquisitions
Assets acquired and liabilities assumed
Cash and cash equivalents	34.6
Accounts receivable	81.2
Assets held for sale	125.1
Inventories	155.1
Other current assets	18
Property, plant and equipment, net	55.5
Identifiable intangible assets, excluding acquired IPR&D	703.5
Acquired IPR&D	63
Other non-current assets	1.9
Current liabilities	-170.2
Long-term debt, including current portion	-11.2
Deferred income taxes, net	-80
Other non-current liabilities	-13.5
Total identifiable net assets	963
Noncontrolling interest	-14.8
Goodwill	400.9
Total fair value of consideration transferred	1,349.10
Gross contractual amount of trade accounts receivable acquired	88
Expected uncollectible of trade accounts receivable acquired	7
2014 Acquisitions | Amounts Recognized as of Acquisition Date (as previously reported)
Assets acquired and liabilities assumed
Cash and cash equivalents		33.6
Accounts receivable		87.7
Assets held for sale		125.7
Inventories		170.4
Other current assets		19.1
Property, plant and equipment, net		58.5
Identifiable intangible assets, excluding acquired IPR&D		697.2
Acquired IPR&D		65.8
Other non-current assets		4
Current liabilities		-152
Long-term debt, including current portion		-11.2
Deferred income taxes, net		-116
Other non-current liabilities		-13.4
Total identifiable net assets		969.4
Noncontrolling interest		-15
Goodwill		410.4
Total fair value of consideration transferred		1,364.80
2014 Acquisitions | Measurement Period Adjustments
Assets acquired and liabilities assumed
Cash and cash equivalents		1
Accounts receivable		-6.5
Assets held for sale		-0.6
Inventories		-15.3
Other current assets		-1.1
Property, plant and equipment, net		-3
Identifiable intangible assets, excluding acquired IPR&D		6.3
Acquired IPR&D		-2.8
Other non-current assets		-2.1
Current liabilities		-18.2
Long-term debt, including current portion		0
Deferred income taxes, net		36
Other non-current liabilities		-0.1
Total identifiable net assets		-6.4
Noncontrolling interest		0.2
Goodwill		-9.5
Total fair value of consideration transferred		-15.7
Developed Markets
Assets acquired and liabilities assumed
Goodwill	6,999.20	7,115
Developed Markets | 2015 Acquisitions
Assets acquired and liabilities assumed
Goodwill	42
Developed Markets | PreCision Dermatology, Inc.
Assets acquired and liabilities assumed
Goodwill			178
Developed Markets | Solta Medical, Inc.
Assets acquired and liabilities assumed
Goodwill			56
Emerging Markets
Assets acquired and liabilities assumed
Goodwill	2,162.20	2,231.40
Emerging Markets | 2015 Acquisitions
Assets acquired and liabilities assumed
Goodwill	9
Emerging Markets | Solta Medical, Inc.
Assets acquired and liabilities assumed
Goodwill			$38

BUSINESS_COMBINATIONS_Identifi

BUSINESS COMBINATIONS - Identifiable intangible assets (Details) (USD $)	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
2015 Acquisitions
Business Acquisition [Line Items]
Weighted- Average Useful Lives (Years)	8 years
Total identifiable intangible assets acquired	$851.80
2015 Acquisitions | Product brands
Business Acquisition [Line Items]
Weighted- Average Useful Lives (Years)	7 years
Total identifiable intangible assets acquired	580.4
2015 Acquisitions | Product rights
Business Acquisition [Line Items]
Weighted- Average Useful Lives (Years)	3 years
Total identifiable intangible assets acquired	42.6
2015 Acquisitions | Partner relationships
Business Acquisition [Line Items]
Weighted- Average Useful Lives (Years)	8 years
Total identifiable intangible assets acquired	7.8
2015 Acquisitions | Technology/know-how
Business Acquisition [Line Items]
Weighted- Average Useful Lives (Years)	10 years
Total identifiable intangible assets acquired	219
2015 Acquisitions | Other
Business Acquisition [Line Items]
Weighted- Average Useful Lives (Years)	6 years
Total identifiable intangible assets acquired	2
2014 Acquisitions
Business Acquisition [Line Items]
Weighted- Average Useful Lives (Years)		10 years
Total identifiable intangible assets acquired	703.5
2014 Acquisitions | Amounts Recognized as of Acquisition Date (as previously reported)
Business Acquisition [Line Items]
Total identifiable intangible assets acquired		697.2
2014 Acquisitions | Measurement Period Adjustments
Business Acquisition [Line Items]
Total identifiable intangible assets acquired		6.3
2014 Acquisitions | Product brands
Business Acquisition [Line Items]
Weighted- Average Useful Lives (Years)		10 years
Total identifiable intangible assets acquired	514.3
2014 Acquisitions | Product brands | Amounts Recognized as of Acquisition Date (as previously reported)
Business Acquisition [Line Items]
Total identifiable intangible assets acquired		506
2014 Acquisitions | Product brands | Measurement Period Adjustments
Business Acquisition [Line Items]
Total identifiable intangible assets acquired		8.3
2014 Acquisitions | Product rights
Business Acquisition [Line Items]
Weighted- Average Useful Lives (Years)		8 years
Total identifiable intangible assets acquired	91.9
2014 Acquisitions | Product rights | Amounts Recognized as of Acquisition Date (as previously reported)
Business Acquisition [Line Items]
Total identifiable intangible assets acquired		95.2
2014 Acquisitions | Product rights | Measurement Period Adjustments
Business Acquisition [Line Items]
Total identifiable intangible assets acquired		-3.3
2014 Acquisitions | Corporate brand
Business Acquisition [Line Items]
Weighted- Average Useful Lives (Years)		15 years
Total identifiable intangible assets acquired	30.6
2014 Acquisitions | Corporate brand | Amounts Recognized as of Acquisition Date (as previously reported)
Business Acquisition [Line Items]
Total identifiable intangible assets acquired		28.9
2014 Acquisitions | Corporate brand | Measurement Period Adjustments
Business Acquisition [Line Items]
Total identifiable intangible assets acquired		1.7
2014 Acquisitions | In-licensed products
Business Acquisition [Line Items]
Weighted- Average Useful Lives (Years)		9 years
Total identifiable intangible assets acquired	1.1
2014 Acquisitions | In-licensed products | Amounts Recognized as of Acquisition Date (as previously reported)
Business Acquisition [Line Items]
Total identifiable intangible assets acquired		1.5
2014 Acquisitions | In-licensed products | Measurement Period Adjustments
Business Acquisition [Line Items]
Total identifiable intangible assets acquired		-0.4
2014 Acquisitions | Partner relationships
Business Acquisition [Line Items]
Weighted- Average Useful Lives (Years)		9 years
Total identifiable intangible assets acquired	37.5
2014 Acquisitions | Partner relationships | Amounts Recognized as of Acquisition Date (as previously reported)
Business Acquisition [Line Items]
Total identifiable intangible assets acquired		37.5
2014 Acquisitions | Partner relationships | Measurement Period Adjustments
Business Acquisition [Line Items]
Total identifiable intangible assets acquired		0
2014 Acquisitions | Other
Business Acquisition [Line Items]
Weighted- Average Useful Lives (Years)		9 years
Total identifiable intangible assets acquired	28.1
2014 Acquisitions | Other | Amounts Recognized as of Acquisition Date (as previously reported)
Business Acquisition [Line Items]
Total identifiable intangible assets acquired		28.1
2014 Acquisitions | Other | Measurement Period Adjustments
Business Acquisition [Line Items]
Total identifiable intangible assets acquired		0

BUSINESS_COMBINATIONS_Pro_form

BUSINESS COMBINATIONS - Pro forma impact of business combinations (Details) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Pro forma of consolidated results of operations
Revenues	$2,270.40	$2,056.40
Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.	$93.80	($73.90)
Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:
Basic (in usd per share)	$0.28	($0.22)
Diluted (in usd per share)	$0.27	($0.22)

RESTRUCTURING_INTEGRATION_AND_2

RESTRUCTURING, INTEGRATION AND OTHER COSTS - Narrative (Details) (USD $)	3 Months Ended		12 Months Ended		20 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2015
	employee
Cost-rationalization and integration initiatives
Restructuring and acquisition-related costs since acquisition date					$578
Restructuring, integration and other costs	55	133.6
Acquisition-related costs	9.8	1.5
B&L
Cost-rationalization and integration initiatives
Restructuring, integration and other costs	3.9	29	69.7	234.1
Restructuring costs related to employee termination					56
Restructuring expenses related to acquisition					311
Integration expenses related to acquisition	5	69			254
Acquisition-related costs					13
Approximate number of employees expected to be terminated	3,000
Payments for Merger Related Costs ($8 and $57 for integration and $16 for restructuring)	8	57
B&L | Maximum
Cost-rationalization and integration initiatives
Restructuring and acquisition-related costs since acquisition date	600
Employee Termination Costs - Share-Based Compensation | B&L
Cost-rationalization and integration initiatives
Restructuring, integration and other costs	0		0	52.8
Employee Termination Costs | B&L
Cost-rationalization and integration initiatives
Payments for Merger Related Costs ($8 and $57 for integration and $16 for restructuring)	$16

RESTRUCTURING_INTEGRATION_AND_3

RESTRUCTURING, INTEGRATION AND OTHER COSTS (Details 2) (USD $)	3 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Restructuring reserve
Costs incurred and/or charged to expense	$55	$133.60
B&L
Restructuring reserve
Balance at the beginning of the period	23.3	100.3	100.3	0
Costs incurred and/or charged to expense	3.9	29	69.7	234.1
Cash payments	-13.9	-54	-135.6	-138.4
Non-cash adjustments	-2.7		-11.1	4.6
Balance at the end of the period	10.6		23.3	100.3
B&L | Employee Termination Costs - Severance and Related Benefits
Restructuring reserve
Balance at the beginning of the period	18.9	89.3	89.3	0
Costs incurred and/or charged to expense	3		46	155.7
Cash payments	-12.6		-110.7	-77.8
Non-cash adjustments	-1.5		-5.7	11.4
Balance at the end of the period	7.8		18.9	89.3
B&L | Employee Termination Costs - Share-Based Compensation
Restructuring reserve
Balance at the beginning of the period	0	0	0	0
Costs incurred and/or charged to expense	0		0	52.8
Cash payments	0		0	-52.8
Non-cash adjustments	0		0	0
Balance at the end of the period	0		0	0
B&L | IPR&D Termination Costs
Restructuring reserve
Balance at the beginning of the period	0	0	0	0
Costs incurred and/or charged to expense	0		0	0
Cash payments	0		0	0
Non-cash adjustments	0		0	0
Balance at the end of the period	0		0	0
B&L | Contract Termination, Facility Closure and Other Costs
Restructuring reserve
Balance at the beginning of the period	4.4	11	11	0
Costs incurred and/or charged to expense	0.9		23.7	25.6
Cash payments	-1.3		-24.9	-7.8
Non-cash adjustments	-1.2		-5.4	-6.8
Balance at the end of the period	$2.80		$4.40	$11

RESTRUCTURING_INTEGRATION_AND_4

RESTRUCTURING, INTEGRATION AND OTHER COSTS (Details 3) (Other Restructuring, Integration-related and Other Costs, USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Other Restructuring, Integration-related and Other Costs
Cost-rationalization and integration initiatives
Other restructuring, integration-related costs incurred	$46	$35
Integration consulting, duplicate labor, transition service, and other	23	11
Severance costs	21	12
Facility closure costs	1	8
Other costs, including non-personnel manufacturing integration costs	1	4
Cash payment made	$27	$26

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details)

3 Months Ended

0 Months Ended

3 Months Ended

Mar. 31, 2015

Mar. 31, 2015

Dec. 31, 2014

Mar. 31, 2015

Dec. 31, 2014

Mar. 31, 2015

Dec. 31, 2014

Mar. 31, 2015

Dec. 31, 2014

Mar. 27, 2015

Mar. 31, 2015

Mar. 27, 2015

Dec. 31, 2014

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Recurring basis

Recurring basis

Quoted Prices in Active Markets for Identical Assets (Level 1)

Quoted Prices in Active Markets for Identical Assets (Level 1)

Significant Other Observable Inputs (Level 2)

Significant Other Observable Inputs (Level 2)

Significant Unobservable Inputs (Level 3)

Significant Unobservable Inputs (Level 3)

4.50% Senior Notes due May 2023

4.50% Senior Notes due May 2023

4.50% Senior Notes due May 2023

4.50% Senior Notes due May 2023

Foreign Exchange Forward

Foreign Exchange Forward

Foreign Exchange Forward

USD ($)

USD ($)

Recurring basis

Recurring basis

Recurring basis

Recurring basis

Recurring basis

Recurring basis

EUR (€)

Designated as Hedging Instrument

Accrued and Other Current Liabilities

Foreign Exchange and Other

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

USD ($)

USD ($)

Assets:

Cash equivalents

$120,300,000

$4,600,000

$115,000,000

$2,800,000

$5,300,000

$1,800,000

$0

$0

Restricted cash

10,354,900,000

9,100,000

10,354,900,000

9,100,000

0

0

0

0

Liabilities:

Foreign exchange contracts

-26,600,000

0

0

0

-26,600,000

0

0

0

Acquisition-related contingent consideration

-385,200,000

-308,800,000

0

0

0

0

-385,200,000

-308,800,000

Highly liquid investments, maturity period (in months)

3 months

Foreign currency forward-exchange contract

1,530,000,000

Proceeds from Issuance of Debt

1,500,000,000

Debt instrument, interest rate, stated percentage

4.50%

4.50%

4.50%

Foreign exchange contract included on the Balance Sheet

27,000,000

Foreign exchange contracts included on the Income Statement

$27,000,000

FAIR_VALUE_MEASUREMENTS_Detail1

FAIR VALUE MEASUREMENTS (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Assets Measured at Fair Value on a Recurring Basis
Fair Value, Assets Level 1 to Level 2 Transfers, Value	$0
Significant Other Observable Inputs (Level 2) | Prepaid Expenses and Other Current Assets
Assets Measured at Fair Value on a Recurring Basis
Carrying value of time deposits	$25,000,000	$43,000,000

FAIR_VALUE_MEASUREMENTS_Detail2

FAIR VALUE MEASUREMENTS (Details 3) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation
Acquisition-related contingent consideration gain (loss)	($7,100,000)	($8,900,000)
Acquisition-related contingent consideration
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation
Balance at the beginning of the period	-308,800,000
Issuances	-90,200,000
Payments	14,500,000
Net Unrealized Loss	-7,100,000
Foreign Exchange	3,900,000
Release from Restricted Cash	2,500,000
Balance at the end of the period	-385,200,000
Acquisition-related contingent consideration gain (loss)	-7,000,000
Transfers Into or Out of Level 3	$0

INVENTORIES_Details

INVENTORIES (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$239.10	$191.10
Work in process	101.1	94.2
Finished goods	658.7	665.3
Total Inventories	$998.90	$950.60

INTANGIBLE_ASSETS_AND_GOODWILL2

INTANGIBLE ASSETS AND GOODWILL (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Finite-lived intangible assets:
Gross Carrying Amount	$14,991.60	$14,408.90
Accumulated Amortization, Including Impairments	-5,426.10	-5,140.60
Net Carrying Amount	9,565.50	9,268.30
Total intangible assets
Gross Carrying Amount	16,980.70	16,396.50
Net Carrying Amount	11,554.60	11,255.90
Acquired IPR&D
Finite-lived intangible assets:
Accumulated Amortization, Including Impairments	0	0
Indefinite-lived intangible assets:
Indefinite-lived intangible assets	291.6	290.1
Corporate brand
Finite-lived intangible assets:
Accumulated Amortization, Including Impairments	0	0
Indefinite-lived intangible assets:
Indefinite-lived intangible assets	1,697.50	1,697.50
Product brands
Finite-lived intangible assets:
Gross Carrying Amount	10,691.40	10,320.20
Accumulated Amortization, Including Impairments	-3,763.80	-3,579.80
Net Carrying Amount	6,927.60	6,740.40
Corporate brand
Finite-lived intangible assets:
Gross Carrying Amount	352.7	364.2
Accumulated Amortization, Including Impairments	-67.4	-65.2
Net Carrying Amount	285.3	299
Product rights
Finite-lived intangible assets:
Gross Carrying Amount	3,248.20	3,225.90
Accumulated Amortization, Including Impairments	-1,360.80	-1,263.80
Net Carrying Amount	1,887.40	1,962.10
Partner relationships
Finite-lived intangible assets:
Gross Carrying Amount	203	223.1
Accumulated Amortization, Including Impairments	-102.5	-107.5
Net Carrying Amount	100.5	115.6
Technology and other
Finite-lived intangible assets:
Gross Carrying Amount	496.3	275.5
Accumulated Amortization, Including Impairments	-131.6	-124.3
Net Carrying Amount	$364.70	$151.20

INTANGIBLE_ASSETS_AND_GOODWILL3

INTANGIBLE ASSETS AND GOODWILL (Details 2) (USD $)	Mar. 31, 2015
In Millions, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]
2015	$1,466.40
2016	1,379.50
2017	1,317.20
2018	1,184.10
2019	$1,043.60

INTANGIBLE_ASSETS_AND_GOODWILL4

INTANGIBLE ASSETS AND GOODWILL (Details 3) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015
Change in the carrying amount of goodwill
Balance at the beginning of the period	$9,346.40
Additions	50.8
Adjustments	4.6
Foreign exchange and other	-240.4
Balance at the end of the period	9,161.40
Developed Markets
Change in the carrying amount of goodwill
Balance at the beginning of the period	7,115
Additions	41.4
Adjustments	4
Foreign exchange and other	-161.2
Balance at the end of the period	6,999.20
Emerging Markets
Change in the carrying amount of goodwill
Balance at the beginning of the period	2,231.40
Additions	9.4
Adjustments	0.6
Foreign exchange and other	-79.2
Balance at the end of the period	$2,162.20

LONGTERM_DEBT_Details

LONG-TERM DEBT (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Feb. 17, 2015	Jan. 30, 2015	Mar. 27, 2015
In Millions, unless otherwise specified
Long-term debt, net of unamortized debt discount
Total long-term debt	$26,020.70	$15,254.60
Less current portion	-122.8	-0.9
Total long-term debt	25,897.90	15,253.70
Series A-1 Tranche A Term Loan Facility
Long-term debt, net of unamortized debt discount
Total long-term debt	139.1	139.6
Series A-2 Tranche A Term Loan Facility
Long-term debt, net of unamortized debt discount
Total long-term debt	135.3	135.7
Series A-3 Tranche A Term Loan Facility
Long-term debt, net of unamortized debt discount
Total long-term debt	1,877.30	1,637.90
Series D-2 Tranche B Term Loan Facility
Long-term debt, net of unamortized debt discount
Total long-term debt	1,084.10	1,089.70
Series C-2 Tranche B Term Loan Facility
Long-term debt, net of unamortized debt discount
Total long-term debt	834	838.3
Series E-1 Tranche B Term Loan Facility
Long-term debt, net of unamortized debt discount
Total long-term debt	2,529.50	2,544.90
6.875% Senior Notes due in December 2018
Long-term debt, net of unamortized debt discount
Debt instrument, interest rate, stated percentage	6.88%	6.88%	6.88%	6.88%
Total long-term debt	0	497.7
7.00% Senior Notes due in October 2020
Long-term debt, net of unamortized debt discount
Debt instrument, interest rate, stated percentage	7.00%	7.00%
Total long-term debt	687.6	687.5
6.75% Senior Notes due in August 2021
Long-term debt, net of unamortized debt discount
Debt instrument, interest rate, stated percentage	6.75%	6.75%
Total long-term debt	650	650
7.25% Senior Notes due in July 2022
Long-term debt, net of unamortized debt discount
Debt instrument, interest rate, stated percentage	7.25%	7.25%
Total long-term debt	543.4	543.2
6.375% Senior Notes due in October 2020
Long-term debt, net of unamortized debt discount
Debt instrument, interest rate, stated percentage	6.38%	6.38%
Total long-term debt	2,226.60	2,225.60
6.75% Senior Notes due in August 2018
Long-term debt, net of unamortized debt discount
Debt instrument, interest rate, stated percentage	6.75%	6.75%
Total long-term debt	1,586.80	1,585.80
7.50% Senior Notes due in July 2021
Long-term debt, net of unamortized debt discount
Debt instrument, interest rate, stated percentage	7.50%	7.50%
Total long-term debt	1,609.10	1,608.40
5.625% Senior Notes due in December 2021
Long-term debt, net of unamortized debt discount
Debt instrument, interest rate, stated percentage	5.63%	5.63%
Total long-term debt	892.9	892.6
5.50% Senior Notes due March 2023
Long-term debt, net of unamortized debt discount
Debt instrument, interest rate, stated percentage	5.50%	5.50%		5.50%
Total long-term debt	991.7	0
5.375% Senior Notes due March 2020
Long-term debt, net of unamortized debt discount
Debt instrument, interest rate, stated percentage	5.38%	5.38%			5.38%
Total long-term debt	1,977.60	0
5.875% Senior Notes due May 2023
Long-term debt, net of unamortized debt discount
Debt instrument, interest rate, stated percentage	5.88%	5.88%			5.88%
Total long-term debt	3,213.50	0
4.50% Senior Notes due May 2023
Long-term debt, net of unamortized debt discount
Debt instrument, interest rate, stated percentage	4.50%	4.50%			4.50%
Total long-term debt	1,591.50	0
6.125% Senior Notes due April 2025
Long-term debt, net of unamortized debt discount
Debt instrument, interest rate, stated percentage	6.13%	6.13%			6.13%
Total long-term debt	3,213.50	0
Other
Long-term debt, net of unamortized debt discount
Total long-term debt	12.2	12.7
Revolving Credit Facility
Long-term debt, net of unamortized debt discount
Total long-term debt	$225	$165

LONGTERM_DEBT_Details_2

LONG-TERM DEBT (Details 2) (USD $)	0 Months Ended
	Jan. 22, 2015	Feb. 20, 2015	Mar. 31, 2015	Dec. 31, 2014
Long-term debt, net of unamortized debt discount
Long-term debt			$26,020,700,000	$15,254,600,000
Total fair value of long-term debt			26,930,000,000	15,780,000,000
Revolving Credit Facility
Long-term debt, net of unamortized debt discount
Long-term debt			225,000,000	165,000,000
Senior Secured Credit Facilities
Maximum borrowing capacity	1,500,000,000
Effective rate (as a percent)			2.45%
Series A-3 Tranche A Term Loan Facility
Long-term debt, net of unamortized debt discount
Long-term debt			1,877,300,000	1,637,900,000
Senior Secured Credit Facilities
Proceeds from Issuance of Debt	250,000,000
Effective rate (as a percent)			2.38%
Senior Secured Credit Facilities
Senior Secured Credit Facilities
Proceeds from Issuance of Debt		5,150,000,000
Series A-1 Tranche A Term Loan Facility
Long-term debt, net of unamortized debt discount
Long-term debt			139,100,000	139,600,000
Senior Secured Credit Facilities
Effective rate (as a percent)			2.39%
Series A-2 Tranche A Term Loan Facility
Long-term debt, net of unamortized debt discount
Long-term debt			135,300,000	135,700,000
Senior Secured Credit Facilities
Effective rate (as a percent)			2.38%
Series D-2 Tranche B Term Loan Facility
Long-term debt, net of unamortized debt discount
Long-term debt			$1,084,100,000	$1,089,700,000
Senior Secured Credit Facilities
Effective rate (as a percent)			3.50%

LONGTERM_DEBT_Details_3

LONG-TERM DEBT (Details 3)

0 Months Ended

3 Months Ended

0 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

3 Months Ended

Mar. 27, 2015

Mar. 31, 2015

Mar. 31, 2014

Dec. 31, 2014

Jan. 30, 2015

Mar. 31, 2015

Jan. 30, 2015

Dec. 31, 2014

Feb. 17, 2015

Mar. 31, 2015

Feb. 17, 2015

Jan. 30, 2015

Dec. 31, 2014

Mar. 27, 2015

Mar. 31, 2015

Mar. 27, 2015

Dec. 31, 2014

Mar. 27, 2015

Mar. 31, 2015

Mar. 27, 2015

Dec. 31, 2014

Mar. 27, 2015

Mar. 31, 2015

Mar. 27, 2015

Dec. 31, 2014

Mar. 27, 2015

Mar. 31, 2015

Mar. 27, 2015

Dec. 31, 2014

Mar. 27, 2015

Feb. 20, 2015

Mar. 27, 2015

Mar. 31, 2015

Feb. 20, 2015

Feb. 20, 2015

Feb. 20, 2015

Feb. 20, 2015

Feb. 20, 2015

Feb. 20, 2015

Feb. 20, 2015

Mar. 31, 2015

USD ($)

USD ($)

USD ($)

USD ($)

5.50% Senior Notes due March 2023

5.50% Senior Notes due March 2023

5.50% Senior Notes due March 2023

5.50% Senior Notes due March 2023

6.875% Senior Notes due in December 2018

6.875% Senior Notes due in December 2018

6.875% Senior Notes due in December 2018

6.875% Senior Notes due in December 2018

6.875% Senior Notes due in December 2018

5.375% Senior Notes due March 2020

5.375% Senior Notes due March 2020

5.375% Senior Notes due March 2020

5.375% Senior Notes due March 2020

5.875% Senior Notes due May 2023

5.875% Senior Notes due May 2023

5.875% Senior Notes due May 2023

5.875% Senior Notes due May 2023

4.50% Senior Notes due May 2023

4.50% Senior Notes due May 2023

4.50% Senior Notes due May 2023

4.50% Senior Notes due May 2023

6.125% Senior Notes due April 2025

6.125% Senior Notes due April 2025

6.125% Senior Notes due April 2025

6.125% Senior Notes due April 2025

5.375%, 5.875%, 4.50% and 6.125% Senior Unsecured Notes

Senior Secured Credit Facilities

Salix

Salix

Salix

Salix

Salix

Salix

Salix

Salix

Salix

Salix

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

5.375%, 5.875%, 4.50% and 6.125% Senior Unsecured Notes

Senior Secured Credit Facilities

Senior Unsecured Bridge Facility

Incremental Term Loan B Facility

Incremental Term Loan Facilities

Series F Tranche B Term Loan Facility

Series A-4 Tranche Term Loan Facility

Amended and Restated Commitment Letter

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Debt Instrument [Line Items]

Proceeds from Issuance of Debt

$1,000,000,000

$2,000,000,000

$3,250,000,000

€ 1,500,000,000

$3,250,000,000

$5,150,000,000

$10,100,000,000

Interest rate on debt (as a percent)

5.50%

5.50%

5.50%

6.88%

6.88%

6.88%

6.88%

5.38%

5.38%

5.38%

5.88%

5.88%

5.88%

4.50%

4.50%

4.50%

6.13%

6.13%

6.13%

Underwriting fees

8,000,000

114,000,000

Restricted cash

10,354,900,000

9,100,000

10,340,000,000

Issuance of long-term debt, net of discount

12,004,400,000

360,600,000

992,000,000

Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings

40.00%

40.00%

Redemption price, using proceeds from certain equity offerings as a percentage of the principal amount

105.50%

105.38%

105.88%

104.50%

106.13%

Redemption price as a percentage of principal amount as per the merger agreement

101.00%

101.00%

Aggregate principal amount of notes repurchased

500,000,000

Repurchases of convertible debt

524,000,000

Call premium

17,000,000

Loss on extinguishment of debt

20,000,000

93,700,000

20,000,000

Maximum borrowing capacity

5,550,000,000

9,600,000,000

15,250,000,000

5,150,000,000

4,150,000,000

1,000,000,000

Deferred financing costs expensed

72,000,000

Issuance of common stock

$1,450,000,000

$1,431,900,000

$1,450,000,000

SHAREBASED_COMPENSATION_Detail

SHARE-BASED COMPENSATION (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Components and classification of share-based compensation expense
Share-based compensation expense	$35	$24.80
Research and development expenses
Components and classification of share-based compensation expense
Share-based compensation expense	1.5	1.4
Selling, general and administrative expenses
Components and classification of share-based compensation expense
Share-based compensation expense	33.5	23.4
Stock options
Components and classification of share-based compensation expense
Share-based compensation expense	3.9	5.1
RSUs
Components and classification of share-based compensation expense
Share-based compensation expense	$31.10	$19.70

SHAREBASED_COMPENSATION_Narrat

SHARE-BASED COMPENSATION - Narrative (Details) (USD $)	3 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Stock options
Stock option activity
Granted (in shares)	72	72
Weighted average exercise price (in usd per share)	$192.62	$144.86
Weighted average grant date fair value of stock options (in usd per share)	$63.11	$53.29
Time-based RSUs
Stock option activity
Granted (in shares)	5	60
Weighted average grant date fair value of stock options (in usd per share)	$196.71	$137.66
Performance-based RSUs
Stock option activity
Granted (in shares)	600	99
Weighted average grant date fair value of stock options (in usd per share)	$307.21	$248.97
RSUs
Stock option activity
Remaining unrecognized compensation expense related to non-vested awards	$335
Weighted average service period over which compensation cost is expected to be recognized (in years)	3 years 11 months 1 day

PENSION_AND_POSTRETIREMENT_EMP2

PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of net periodic benefit cost (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
U.S. Pension Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	$0.40	$0.10
Interest cost	2.4	2.7
Expected return on plan assets	-3.6	-3.7
Amortization of prior service credit	0	0
Amortization of net loss	0	0
Net periodic (benefit) cost	-0.8	-0.9
Non-U.S. Pension Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	0.8	1
Interest cost	1.6	2.2
Expected return on plan assets	-2	-2
Amortization of prior service credit	-0.1	0
Amortization of net loss	0.4	0
Net periodic (benefit) cost	0.7	1.2
Postretirement Benefit Plan
Defined Benefit Plan Disclosure [Line Items]
Service cost	0.5	0.4
Interest cost	0.5	0.6
Expected return on plan assets	-0.1	-0.1
Amortization of prior service credit	-0.6	-0.6
Amortization of net loss	0	0
Net periodic (benefit) cost	$0.30	$0.30

PENSION_AND_POSTRETIREMENT_EMP3

PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015
U.S. Pension Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined benefit plan contributions made	$2
Estimated Company contributions in current fiscal year	10
Non-U.S. Pension Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined benefit plan contributions made	1
Estimated Company contributions in current fiscal year	$7

SHAREHOLDERS_EQUITY_Details

SHAREHOLDERS' EQUITY (Details) (USD $)	0 Months Ended	3 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 27, 2015	Mar. 31, 2015	Mar. 31, 2014
Increase (Decrease) in Shareholders' Equity
Beginning Balance (in shares)		334,402,964
Beginning Balance		$5,434.50	$5,233.30
Issuance of common stock (in shares)	7,286,432
Issuance of common stock	1,450	1,431.90
Common shares issued under share-based compensation plans		14.5	3.5
Share-based compensation		35	24.8
Employee withholding taxes related to share-based awards		-21.2	-27.7
Tax benefits from stock options exercised		17.9	1.2
Acquisition of noncontrolling interest			-3.3
Total before comprehensive income (loss)		6,912.60	5,231.80
Comprehensive loss:
Net income (loss)		74.5	-20.3
Other comprehensive loss		-411.9	-8
Comprehensive loss		-337.4	-28.3
Ending Balance (in shares)		342,266,409
Ending Balance		6,575.20	5,203.50
Common Shares
Increase (Decrease) in Shareholders' Equity
Beginning Balance (in shares)		334,400,000	333,000,000
Beginning Balance		8,349.20	8,301.20
Issuance of common stock (in shares)		7,300,000
Issuance of common stock		1,431.90
Common shares issued under share-based compensation plans (in shares)		600,000	500,000
Common shares issued under share-based compensation plans		29.2	15
Total before comprehensive income (loss) (in shares)		342,300,000	333,500,000
Total before comprehensive income (loss)		9,810.30	8,316.20
Comprehensive loss:
Ending Balance (in shares)		342,300,000	333,500,000
Ending Balance		9,810.30	8,316.20
Additional Paid-In Capital
Increase (Decrease) in Shareholders' Equity
Beginning Balance		243.9	228.8
Common shares issued under share-based compensation plans		-14.7	-11.5
Share-based compensation		35	24.8
Employee withholding taxes related to share-based awards		-21.2	-27.7
Tax benefits from stock options exercised		17.9	1.2
Acquisition of noncontrolling interest			-1.1
Total before comprehensive income (loss)		260.9	214.5
Comprehensive loss:
Ending Balance		260.9	214.5
Accumulated Deficit
Increase (Decrease) in Shareholders' Equity
Beginning Balance		-2,365	-3,278.50
Total before comprehensive income (loss)		-2,365	-3,278.50
Comprehensive loss:
Net income (loss)		73.7	-22.6
Ending Balance		-2,291.30	-3,301.10
Accumulated Other Comprehensive Loss
Increase (Decrease) in Shareholders' Equity
Beginning Balance		-915.9	-132.8
Total before comprehensive income (loss)		-915.9	-132.8
Comprehensive loss:
Other comprehensive loss		-411.7	-7.2
Ending Balance		-1,327.60	-140
Valeant Pharmaceuticals International, Inc. Shareholders’ Equity
Increase (Decrease) in Shareholders' Equity
Beginning Balance		5,312.20	5,118.70
Issuance of common stock		1,431.90
Common shares issued under share-based compensation plans		14.5	3.5
Share-based compensation		35	24.8
Employee withholding taxes related to share-based awards		-21.2	-27.7
Tax benefits from stock options exercised		17.9	1.2
Acquisition of noncontrolling interest			-1.1
Total before comprehensive income (loss)		6,790.30	5,119.40
Comprehensive loss:
Net income (loss)		73.7	-22.6
Other comprehensive loss		-411.7	-7.2
Comprehensive loss		-338	-29.8
Ending Balance		6,452.30	5,089.60
Noncontrolling Interest
Increase (Decrease) in Shareholders' Equity
Beginning Balance		122.3	114.6
Acquisition of noncontrolling interest			-2.2
Total before comprehensive income (loss)		122.3	112.4
Comprehensive loss:
Net income (loss)		0.8	2.3
Other comprehensive loss		-0.2	-0.8
Comprehensive loss		0.6	1.5
Ending Balance		$122.90	$113.90

SHAREHOLDERS_EQUITY_Narrative_

SHAREHOLDERS' EQUITY - Narrative (Details) (USD $)	0 Months Ended	3 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 27, 2015	Mar. 31, 2015	Mar. 27, 2015
Stockholders' Equity Note [Abstract]
Issuance of common stock (in shares)	7,286,432
Price per share (in dollars per share)			$199
Issuance of common stock	$1,450	$1,431.90
Issuance costs	$18
Additional purchase option as a percentage of shares issued in IPO, maximum	15.00%

ACCUMULATED_OTHER_COMPREHENSIV2

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Components of accumulated other comprehensive loss
Balance at the beginning of the period	($915.90)	($132.80)
Foreign currency translation adjustment	-411.3	-6.6
Pension adjustment	-0.4	-0.6
Balance at the end of the period	-1,327.60	-140
Foreign Currency Translation Adjustment
Components of accumulated other comprehensive loss
Balance at the beginning of the period	-886.5	-170.3
Foreign currency translation adjustment	-411.3	-6.6
Pension adjustment	0	0
Balance at the end of the period	-1,297.80	-176.9
Pension Adjustment
Components of accumulated other comprehensive loss
Balance at the beginning of the period	-29.4	37.5
Foreign currency translation adjustment	0	0
Pension adjustment	-0.4	-0.6
Balance at the end of the period	($29.80)	$36.90

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Income tax Expense Benefit
Income tax expense (benefit)	$80.90	$25.10
Valuation allowance against deferred tax assets	940		859
Unrecognized tax benefits including interest and penalties	345
Unrecognized tax benefits related to interest and penalties	40
Portion of unrecognized tax benefits, if recognized, would reduce the Company's effective tax rate	106
Accrued interest related to unrecognized tax benefits	33
Accrued penalties related to unrecognized tax benefits	7
Outside of Canada
Income tax Expense Benefit
Income tax expense (benefit)	80
Canada
Income tax Expense Benefit
Income tax expense (benefit)	$1

EARNINGS_LOSS_PER_SHARE_Detail

EARNINGS (LOSS) PER SHARE (Details) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Earnings Per Share [Abstract]
Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.	$73.70	($22.60)
Basic weighted-average number of common shares outstanding	336.8	334.9
Diluted effect of stock options, RSUs and other (in shares)	6.6	0
Diluted weighted-average number of common shares outstanding	343.4	334.9
Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:
Basic (in usd per share)	$0.22	($0.07)
Diluted (in usd per share)	$0.21	($0.07)

EARNINGS_LOSS_PER_SHARE_Detail1

EARNINGS (LOSS) PER SHARE (Details 2)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Anti-dilutive shares not included in the computation of diluted earnings per share
Basic weighted-average number of common shares outstanding	336,800,000	334,900,000
Diluted weighted-average number of common shares outstanding		341,500,000
Dilutive effect of stock options and RSUs
Anti-dilutive shares not included in the computation of diluted earnings per share
Dilutive effect of stock options and RSUs (in shares)		6,600,000
Dilutive effect of stock options
Anti-dilutive shares not included in the computation of diluted earnings per share
Dilutive effect of stock options and RSUs (in shares)	143,000	741,000

LEGAL_PROCEEDINGS_Details

LEGAL PROCEEDINGS (Details)

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

0 Months Ended

Mar. 19, 2014

Mar. 17, 2015

Nov. 07, 2014

Mar. 31, 2015

24-May-13

Dec. 04, 2013

Mar. 31, 2015

Dec. 04, 2013

16-May-08

16-May-08

Sep. 11, 2009

Mar. 31, 2015

Apr. 06, 2015

Apr. 09, 2015

Apr. 09, 2015

Mar. 31, 2015

action

Salix

Salix

MoistureLoc

ISTA

Natur Produkt

Natur Produkt

Natur Produkt

Written plea agreement

Non-prosecution agreement

Corporate Integrity Agreement

Non Fusarium Cases

Subsequent Event

Subsequent Event

Subsequent Event

Outside the United States

class_action

class_action

B&L

USD ($)

AntiGrippin Trademark

AntiGrippin Trademark

AntiGrippin Trademark

Biovail Pharmaceuticals, Inc.

Biovail Pharmaceuticals, Inc.

Biovail Pharmaceuticals, Inc.

MoistureLoc

complaint

Natur Produkt

Natur Produkt

Fusarium Claims

case

RUB

suit

Other (Income) Expense

USD ($)

USD ($)

B&L

AntiGrippin Trademark

AntiGrippin Trademark

MoistureLoc

lawsuit

USD ($)

case

RUB

Other (Income) Expense

B&L

USD ($)

case

Legal proceedings and other matters

Civil Penalty

$22,000,000

$2,000,000

Obligation term (in years)

5 years

Settlement, amount paid

34,000,000

Litigation settlement, required compliance and ethics period (in years)

3 years

Number of suits filed

2

6

2

2

2

Damages awarded to plaintiff

1,660,000,000

1,660,000,000

Recognized charge loss during period

$50,000,000

$31,000,000

Currently active lawsuits/claims

321

320

2

Number consolidated cases

2

Number of cases settled

630

Number of putative class action cases filed

3

SEGMENT_INFORMATION_Details

SEGMENT INFORMATION (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
	segment
Segment reporting information
Number of operating segments	2
Number of reportable segments	2
Total revenues	$2,190.90	$1,886.20
Total segment profit	74.5	-20.3
Restructuring, integration and other costs	-55	-133.6
In-process research and development impairments and other charges	0	-12
Acquisition-related costs	-9.8	-1.5
Acquisition-related contingent consideration	-7.1	-8.9
Other (expense) income	-6.1	43.3
Operating income	543.4	356.6
Interest income	0.9	1.8
Interest expense	-297.8	-246.5
Loss on extinguishment of debt	-20	-93.7
Foreign exchange and other	-71.1	-13.4
Income before provision for income taxes	155.4	4.8
Share-based compensation expense	35	24.8
Total Segment
Segment reporting information
Total segment profit	690.6	507.4
Corporate
Segment reporting information
Total segment profit	-69.2	-38.1
Share-based compensation expense	24	15
Developed Markets
Segment reporting information
Total revenues	1,764.40	1,421.80
Total segment profit	636	439.3
Developed Markets | 2014 and 2015 Acquisitions
Segment reporting information
Total revenues	208
Emerging Markets
Segment reporting information
Total revenues	426.5	464.4
Total segment profit	54.6	68.1
Emerging Markets | 2014 and 2015 Acquisitions
Segment reporting information
Total revenues	12
Fair Value Adjustment to Inventory and Identifiable Intangible Assets | Developed Markets
Segment reporting information
Total segment profit	314
Fair Value Adjustment to Inventory and Identifiable Intangible Assets | Emerging Markets
Segment reporting information
Total segment profit	$76

SEGMENT_INFORMATION_Details_2

SEGMENT INFORMATION (Details 2) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	$38,565.90	$26,353
Identifiable intangible assets	11,554.60	11,255.90
Goodwill	9,161.40	9,346.40
2015 Acquisitions
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	50.8
Total Segment
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	36,131.30	25,426.30
Corporate
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	2,434.60	926.7
Developed Markets
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	30,106.20	19,093.40
Goodwill	6,999.20	7,115
Developed Markets | 2015 Acquisitions
Segment Reporting, Asset Reconciling Item [Line Items]
Identifiable intangible assets	759
Goodwill	42
Emerging Markets
Segment Reporting, Asset Reconciling Item [Line Items]
Total assets	6,025.10	6,332.90
Goodwill	2,162.20	2,231.40
Emerging Markets | 2015 Acquisitions
Segment Reporting, Asset Reconciling Item [Line Items]
Identifiable intangible assets	93
Goodwill	$9

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (USD $)	0 Months Ended
	Apr. 01, 2015	Feb. 20, 2015
	product
Subsequent Event | Salix
Subsequent events
Enterprise value	$16,000,000,000
Number of products in product portfolio (more than)	20
Par value per share of common stock (in dollars per share)	$0.00
Per share consideration (in usd per share)	$173
Conversion option, amount per share of Salix stock (in usd per share)	$173
Incremental Term Loan Facilities | Salix
Subsequent events
Maximum borrowing capacity		5,150,000,000
Incremental Term Loan Facilities | Subsequent Event
Subsequent events
Original issue discount	21,000,000
Incremental Term Loan Facilities | Subsequent Event | Salix
Subsequent events
Maximum borrowing capacity	5,150,000,000
Series A-4 Tranche Term Loan Facility | Salix
Subsequent events
Maximum borrowing capacity		1,000,000,000
Series A-4 Tranche Term Loan Facility | Subsequent Event
Subsequent events
Maximum borrowing capacity	1,000,000,000
Quarterly amortization rate, starting June 30, 2015 (as a percent)	5.00%
Quarterly amortization rate, starting June 30, 2016 (as a percent)	10.00%
Quarterly amortization rate, starting June 30, 2017 (as a percent)	20.00%
Series F Tranche B Term Loan Facility | Salix
Subsequent events
Maximum borrowing capacity		4,150,000,000
Series F Tranche B Term Loan Facility | Subsequent Event
Subsequent events
Maximum borrowing capacity	$4,150,000,000
Quarterly amortization rate, starting June 30, 2015 (as a percent)	1.00%
Base Rate | Series F Tranche B Term Loan Facility | Subsequent Event
Subsequent events
Variable rate floor (as a percentage)	1.75%
London Interbank Offered Rate (LIBOR) | Series F Tranche B Term Loan Facility | Subsequent Event
Subsequent events
Variable rate floor (as a percentage)	0.75%
Minimum | Base Rate | Series A-4 Tranche Term Loan Facility | Subsequent Event
Subsequent events
Variable rate (as a percentage)	0.75%
Minimum | Base Rate | Series F Tranche B Term Loan Facility | Subsequent Event
Subsequent events
Variable rate (as a percentage)	2.00%
Minimum | London Interbank Offered Rate (LIBOR) | Series A-4 Tranche Term Loan Facility | Subsequent Event
Subsequent events
Variable rate (as a percentage)	1.75%
Minimum | London Interbank Offered Rate (LIBOR) | Series F Tranche B Term Loan Facility | Subsequent Event
Subsequent events
Variable rate (as a percentage)	3.00%
Maximum | Base Rate | Series A-4 Tranche Term Loan Facility | Subsequent Event
Subsequent events
Variable rate (as a percentage)	1.25%
Maximum | Base Rate | Series F Tranche B Term Loan Facility | Subsequent Event
Subsequent events
Variable rate (as a percentage)	2.25%
Maximum | London Interbank Offered Rate (LIBOR) | Series A-4 Tranche Term Loan Facility | Subsequent Event
Subsequent events
Variable rate (as a percentage)	2.25%
Maximum | London Interbank Offered Rate (LIBOR) | Series F Tranche B Term Loan Facility | Subsequent Event
Subsequent events
Variable rate (as a percentage)	3.25%
Restricted Stock | Subsequent Event | Salix
Subsequent events
Conversion option, amount per share of Salix stock (in usd per share)	$173